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ABSTRACT

INVESTIGATING THE IMPACT OF NRMT1 CANCER MUTANTS ON
CATALYTIC SPECIFICITY AND THE DNA DAMAGE RESPONSE

Kaitlyn Marie Shields
June 22, 2018

Protein methylation is an established and critical
posttranslational modification controlling multiple
cellular events.

Alterations in protein methylation have

been implicated in many diseases, including cancer.

My

work focused on the N-terminal trimethylase NRMT1 and the
N-terminal monomethylase NRMT2.

Previous work proposed

that NRMT2 assists NRMT1 by priming its substrates for
trimethylation.

Importantly, NRMT1 mutations have been

found in cancers, and loss of NRMT1 has been shown to
promote oncogenic phenotypes in cancer cells.

Together,

this suggests that altered activities of NRMT1/2 may play a
role in cancer progression.

Although NRMT1/2 are 50%

identical, they differ in key aromatic residues in their

v

active site.

Interestingly, mutation of the corresponding

aromatic residues in the methyltransferase EZH2 (B-cell
lymphoma) changes its activity from a monomethylase to a
trimethylase, conferring oncogenicity.

Therefore, I

hypothesized that the differences in these aromatic
residues are responsible for the distinct catalytic
activities of NRMT1/2.

I also proposed that NRMT1 cancer

mutations are responsible for oncogenic phenotypes.

My

work illustrates that while aromatic residue mutations had
no catalytic effect, both NRMT1 cancer mutants N209I
(endometrial) and P211S (lung) displayed decreased
trimethylase and increased mono-/dimethylase activity.
These mutations are located in the peptide-binding channel
and suggest there may be a second structural region
impacting enzyme specificity.

The mutants also required

greater time and substrate levels to be comparable to WT
NRMT1.

Furthermore, in a cellular context lacking

endogenous NRMT1, the N209I and P211S mutants were
incapable of rescuing trimethylation levels or
proliferation.

Additional preliminary studies suggested a

potential role for NRMT1 in the DNA damage response
pathway.

However, further studies will be required to shed

more light into its cellular function.
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CHAPTER I: INTRODUCTION
POSTTRANSLATIONAL MODIFICATIONS AND THEIR IMPACT ON
MOLECULAR INTERACTIONS AND GENE EXPRESSION

The human genome is predicted to encode approximately
20,000 genes (1-3).

However, the human proteome is

invariably more complex due to post-transcriptional (namely
alternative splicing) and post-translational events.

Such

events allow a single gene to give rise to multiple protein
species, resulting in a proteome that is considerably more
immense and diverse than the accompanying genome.

One

prominent example involves posttranslational modifications
(PTMs) that occur on proteins.
PTMs are covalent modifications that can regulate
protein function through various means, including activity,
enzymatic activation/inactivation, subcellular
localization, as well as protein-protein and protein-DNA
interactions (4-8).

The list of PTMs is extensive, and

includes methylation, acetylation, phosphorylation,
glycosylation, ubiquitination, sumoylation, hydroxylation,
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sulfation, nitrosylation, palmitoylation, as well as a host
of infrequent modifications (4,9-12).
As an example, histones are known to be acetylated,
phosphorylated, methylated, and ubiquitinated (13-16).
These modifications exhibit great clout over transcription,
often by directing chromatin remodeling proteins to open or
close the conformation of the chromatin (17).

One primary

effect of this is increased or decreased accessibility of
transcription factors – whether enhancers or silencers – to
the chromatin, leading to the augmentation or repression of
gene expression (18).
Histone acetylation and phosphorylation are mainly
associated with transcriptional activation (13,15).
Contrastingly, the effect of methylation and ubiquitination
of histones is dichotomous.

While the ubiquitination of

histone H2A is linked with transcriptional repression, the
ubiquitination of histone H2B is linked with
transcriptional activation (19).

Likewise, the methylation

of histone H3 lysine 4 and H3 lysine 36 (H3K4, H3K36) is
correlated with activation; while others are correlated
with repression (i.e. H3K27, H4K20) (20-26).

Thus, unlike

DNA methylation, not all histone methylation events are
repressive.
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Besides the modification of histones, PTMs also occur
on the side chains of non-histone proteins, as well as on
the N- or C-termini of proteins (27-31).

This dissertation

will focus on those that occur at the N-terminus, while
information for a handful of other PTMs can be found in
numerous reviews (14,15,21,32-40).

N-TERMINAL PTMs

N-terminal posttranslational modifications can occur
on the alpha amino group of the initiating methionine, or
on the new alpha amino group if the initiator methionine is
first cleaved by a methionine aminopeptidase (7).

Although

N-terminal methionine excision (NME) is typical for Nterminal PTMs, that is not always the case (41).
Currently, the reported N-terminal PTMs include
methylation, acetylation, propionylation, ubiquitination,
palmitoylation, and myristoylation (6,7,42).
N-terminal myristoylation and palmitoylation result
from the addition of a myristic or palmitic acid, by Nterminal myristoyltransferases or
palmitoylacyltransferases, respectively (7).

This occurs

via the donor molecules myristoyl-CoA or palmitoyl-CoA,
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leading to the attachment of the fatty acid to an Nterminal Gly residue of their substrates.
Propionylation is a recently identified N-terminal
PTM, which is the addition of a molecule derived from
propionic acid.

Currently, less than 20 proteins have been

described to harbor this modification (7).

Unexpectedly,

the enzyme that catalyzes this reaction is the N-terminal
acetyltransferase complex NatA, demonstrating a role for
this enzyme outside of N-terminal acetylation (6,7).
N-terminal ubiquitylation adds a ubiquitin protein to
the free amine of the first N-terminal residue of the
target protein (7).

Like internal polyubiquitylation of

internal residues, E2 and E3 ubiquitin ligase enzymes are
also required.

While internal ubiquitination is most

recognized for its involvement in proteasomal degradation
of target proteins, it also serves in other biological
processes, including the DNA damage response and acting as
a second messenger molecule in signaling pathways (14).
Although N-terminal ubiquitylation has been studied less
than its internal counterpart, the N-terminal modification
presumably also has roles in the aforementioned processes.
N-terminal acetylation is the transfer of an acetyl
moiety from acetyl-CoA to the amine of the N-terminal
residue of a protein by an N-terminal acetyltransferase
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(NAT) (7,42).

NATs recognize the consensus sequence

(Q/R)XXGXX(G/A) (7).

Interestingly, the six different NAT

enzyme subtypes differ in their preference for the
initiating methionine, or the N-terminal residue resultant
from methionine cleavage, indicating subtle differences in
substrate specificity.

Four of the subtypes acetylate the

initiating methionine residue, while the other two
acetylate the N-terminal residue resultant from methionine
cleavage (6).

The addition of acetyl to the N-terminus

changes its positive charge to neutral, which can affect
protein-protein interactions (6,43).
Some examples of N-terminal acetylation targets
include histone H2A and H4, as well as the H3 variant CENPA (6,20).

This modification occurs in the cytoplasm, and

is necessary for functions such as subcellular localization
and protein stability (6).

To date, an N-terminal

deacetylase has not been discovered, so it is considered to
be an irreversible PTM (6,7).

Contrary to the long-held

dogma that a protein could only be N-terminally acetylated
or methylated (and never the other in a different cellular
context, for example), N-terminal acetylation and Nterminal methylation do not preclude each other.

This is

evidenced by MYL9, and other proteins, which have been
reported to undergo either modification (42,44,45).
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Similar to most biological methylation reactions, the
methyl added to the N-terminus comes from the methyl donor
S-Adenosyl methionine (SAM, or AdoMet).

Although N-

terminal methylation has been documented for decades,
enzymes responsible for this process have only been
discovered in the past 10 years (46,47).

NRMT (N-terminal

RCC1 Methyltransferase, also known as NRMT1) was first
discovered in 2010 (47), and subsequently, its homologue
NRMT2, was characterized three years later (46).

Like N-

terminal acetylation, an N-terminal demethylase has also
yet to be identified (6).

As NRMT is the main thrust of

this dissertation, it will be discussed in more detail
below.

EFFECTS OF PROTEIN METHYLATION

Although phosphorylation and acetylation have been
studied most extensively, protein methylation is also a
critical and common PTM that can regulate protein function.
Indeed, this PTM plays crucial roles in chromatin
stability, DNA repair, and transcriptional regulation
(48,49).

N-terminal methylation, specifically, has been

established as a regulator of the DNA damage response and
protein-DNA interactions (6,20,50-52).
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Proteins can be mono-, di-, and trimethylated.

Each

methylation state has a distinct functional readout,
dependent upon the lysine or arginine residue methylated,
as well as the state of methylation (22,48,53-56).
Therefore, methylation of the same residue, yet differing
in methylation state, often confers distinctive functions.
For instance, mono- and trimethylation of histone H4 lysine
20 (H4K20) are means of transcriptional regulation.
Monomethylation of H4K20 promotes transcriptional
elongation, while trimethylation of the same residue pauses
transcription (RNA Polymerase II pausing) (22).

This is a

testament to the cooperation of distinct histone
modifications and subsequent transcriptional effects, as
proposed by Brian Strahl and David Allis in the histone
code hypothesis (49).
When H4K20 becomes monomethylated by SETD8 (SET domain
containing protein 8), the MSL (male-specific lethal)
complex is recruited to gene promoters.

Consequently,

H4K16 is acetylated by MSL, leading to the phosphorylation
of Ser 2 on the C-terminal domain (CTD) of RNA Polymerase
II (Pol II), and releasing it from a paused state into
active transcriptional elongation (22).

On the other hand,

trimethylation of H4K20 by Suv420H2 precludes recruitment
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of the MSL complex, and thus, prevents the acetylation of
H4K16 and the subsequent CTD phosphorylation (22).
A handful of signaling pathways are also regulated by
protein methylation, including the RAS-RAF and Wnt
signaling pathways.

For example, in the Wnt signaling

pathway, the methyltransferases PRMT1 and PRMT7 methylate
the GTPase-activating protein G3BP2, leading to downstream
kinase recruitment and eventual b-catenin activation (21).
The biological impacts or regulation propagated via
protein methylation are partly due to the crosstalk between
the methylation and other PTMs (i.e. the histone code
hypothesis) (21,49).

Its effects are also brought about by

an induction of a positive charge on the nitrogen of the
target residue; whether a positive charge is induced is
dependent on the residue methylated, N-terminal or internal
side chain methylation, and methylation state.

This change

in charge can easily disrupt or change the partners with
which the methylation target interacts, which can have
further downstream effects (32,57).

READERS, WRITERS, AND ERASERS

The terms “Readers,” “Writers,” and “Erasers” are
often used to described various regulators of the PTM
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process.

Readers are the proteins that recognize and bind

to the protein at its site of modification; writers are the
enzymes which perform the modification; and the erasers are
the enzymes which remove the PTM.

Here, I will only

discuss readers, writers, and erasers as they pertain to
methylation.

Lastly, to clarify, substrate specificity

refers to an enzyme’s selectivity for an individual
substrate over another (i.e. Rb over p53).

Catalytic

specificity, however, refers to an enzyme’s differentiation
among different methylation states: whether the enzyme is
able to mono-, di-, or trimethylate its substrate (i.e.
specificity or differentiation for monomethylation over
trimethylation).
As stated previously, writers are the enzymes that add
the PTM to the substrate.

For N-terminal methylation, the

known enzymes are NRMT1 and NRMT2 (46,47).

However, for

histone and internal side chain methylation, a host of
writer enzymes are known (58-62).

Some histone

methyltransferases are specific to their histone targets,
but numerous writers also have non-histone substrates (5860).

Some histone methyltransferases can have the

catalytic specificity for only monomethylation, while
others may have the specificity for all three methylation
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states, or any combination of the three
(22,24,25,55,61,63,64).
The most common methyltransferases are lysine
methyltransferases and arginine methyltransferases
(16,56,58,65-67).

While many lysine methyltransferases are

known by other names, they are generally referred to as the
KMT (lysine methyltransferase) enzymes (68-71).

The family

members include KMT1-8, with each member having multiple
enzyme sub-family members (16).

Within the KMT family,

catalytic specificities range widely (16).

The arginine

methyltransferases are known as PRMTs (protein arginine
methyltransferases) and consist of PRMT1-9 (72).

All PRMTs

mono- and dimethylate substrates; there is no arginine
trimethylation (72).

These are either classified as type I

(asymmetric dimethylation) or type II (symmetric
dimethylation) (72).

Asymmetric dimethylation is

asymmetric as both methyl groups are found on the same
nitrogen atom, found at the end of the arginine side chain
(72).

Symmetric dimethylation is symmetric as one methyl

group each is placed onto two different nitrogen atoms at
the end of the arginine side chain (72).
As previously stated, there is no known eraser for Nterminal methylation, as an N-terminal demethylase has yet
to be discovered (7).

In contrast, various other lysine

10

demethylases (KDMs) have been identified.

The LSD1

(lysine-specific histone demethylase 1) family members are
FAD-dependent enzymes that can remove lysine mono- and
dimethylation through oxidation (73,74).

The JmjC (Jumonji

C)-domain containing demethylases, though, are iron- and 2oxoglutarate-dependent, and remove all three methylation
states via hydroxylation (16,74,75).

Thus far, no enzyme

has been identified to directly remove arginine
methylation.

In this case, methylated arginines are

converted into citrullines by deimination (66).
PTM functional readouts are generally accomplished by
the readers, which contain PTM-specific recognition domains
(64,76,77).

Several domains are capable of lysine and

arginine methylation recognition, including the
chromodomain, Tudor, PHD, MBT, and PWWP domains (76,78-81).
Reader domains recognize a specific methylation state (or
states) on a precise residue, and some domains recognize
more than one substrate (64,76-81).

The different

substrate specificities and/or different methylation state
recognition among reader proteins is due to structural
differences, specifically, the presence of different
residues critical to methyl binding (64,76,77,82).
The methylation recognition leads to recruitment of
protein complexes, such as chromatin remodeling complexes,
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transcription factors, or DNA repair proteins (22,24,5355).

These complexes usually open up (or close) the

chromatin by sliding and repositioning nucleosomes on the
DNA (83), which will lead to further recruitment of
transcription factors, or other proteins, downstream.

One

common class of chromatin remodeling complexes is known as
Mi2/NURD.

This complex has a methylation associating

chromodomain, which has a transcriptionally repressive
effect (84,85).

As such, the reader is ultimately

responsible for the functional outcome of the PTM.

BIOLOGICAL IMPACT OF ALTERED METHYLATION LEVELS

The physiological importance of protein methylation
has been illustrated by multiple studies involving genetic
manipulation of mice (24,63,86-89).

For example, the

conditional knockout of one or both Suv4-20h histone
methyltransferases (responsible for di- and trimethylation
of H4K20) in mice results in perinatal lethality.

Double

knockout animals exhibit a dramatic increase in
monomethylation, and a near loss of di- and trimethylation.
Furthermore, primary mouse embryonic fibroblasts derived
from these double knockout animals exhibit decreased
cellular proliferation as well as a heightened sensitivity
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to DNA damage (24).

This drastic shift in methylation

likely impairs the DNA damage response, as the aberrant
methylation impacts recruitment of DNA damage proteins,
such as 53BP1, to sites of damage with double strand breaks
(DSBs) (24).
In yeast, the DNA checkpoint mediator protein Crb2
becomes localized to sites of DNA damage, and associates
with H4K20 dimethylation.

In cells lacking this

dimethylation, the recruitment of Crb2 to DNA damage is
abolished, resulting in impaired checkpoint function (53).
In another example, SET8 depletion in Drosophila, and the
subsequent loss of H4K20 monomethylation, has been shown to
be detrimental to cell viability, nucleosome dynamics, and
nuclear arrangement (61).
Altered methylation patterns have also been
demonstrated to play a role in many cancers, including
leukemia, lymphoma, lung cancer, and breast cancer, among
others (63,87-90).

Half of acute myeloid leukemia (AML)

patients exhibit abnormal expression of HOX genes (86).
This dysregulated expression prevents recruitment of the
transcription factor AF10, which interacts with the H3K79
histone methyltransferase DOT1L and helps facilitate the
methylation of H3K79 (86).

The lack of AF10 recruitment

inhibits the di- and trimethylation of H3K79, leading to
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appropriately low (or no) HOX gene expression (86,91).

The

interaction between AF10 and DOT1L is crucial for leukemic
oncogenic transformation, as the deletion or inhibition of
either AF10 or DOT1L inhibits the transformation, and
increases mouse survival in xenograft assays (86).
Importantly, this has been attributed to a reduction in the
di- and trimethylation of H3K79 at HOX genes (86).

DNA DAMAGE AND REPAIR

The eukaryotic DNA replication machinery is a large
complex of proteins that include the DNA polymerases.
Despite the high fidelity of polymerases, replication
errors sporadically occur (92).

When a nucleotide is

erroneously incorporated, it is removed by the 3’ à 5’
exonuclease activity of the polymerase (93).
Despite this proofreading mechanism, these errors are
not always repaired, resulting in a mutation – a change in
the DNA sequence of the gene.

The occurrence of mutations,

regardless of the cause or source, are completely random
(92).

Insertion/deletion (indel) mutations, additional

insertions or deletions of base pairs, can also occur,
resulting in a frameshift.

Because they change the number

of bases in the open reading frame, this damage to the DNA
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will alter the triplet codons, and therefore the amino
acids specified by them, giving rise to potentially
deleterious mutations to the protein product of the gene.
However, even if the polymerase error is not detected
by the proofreading exonuclease function, the mistake can
still be corrected through mismatch repair (MMR).

In

eukaryotes, MMR involves numerous MutS and MutL proteins,
the endonucleolytic removal of the erroneous base pairs,
which will be subsequently filled in by DNA polymerases
(94).
Besides replication errors that are continually
propagated this way (assuming they have gone undetected by
all mechanisms of proofreading and correction), or passed
down to offspring, DNA damage also occurs by environmental
factors or chemical mutagen carcinogens.

A chemical

mutagen is a carcinogen only if the induced mutation
results in a phenotypic alteration.
Two of the most common environmental factors causing
DNA damage are cigarette smoke and ultraviolet light (92).
This commonly induces the formation of pyrimidine dimers,
especially thymine dimers, or other lesions such as bulky
DNA adducts (95).

These dimers and adducts locally distort

the DNA, interfering with replication (92).

In prokaryotes

and some eukaryotes, damage such as thymine dimers can be
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repaired outside of DNA excision and filling in the gap
(92).

This process is called photoreactivation, which is

carried out by DNA photolyases.
photolyase homologues (92).

Humans do not contain DNA

Photoreactivation works by

absorption of UV light by the photolyase, and reduction of
FADH- and the pyrimidine dimer, effectively severing the
dimer lesion (96).
Damaged nucleotides which cannot be fixed by direct
repair mechanisms, particularly photoreactivation, can be
corrected by base excision repair (BER).

BER extracts the

damaged base by DNA glycosylases, which split the
glycosidic bond between the nitrogenous base and
deoxyribose sugar (92).

An AP endonuclease then cleaves

and removes the remaining deoxyribose sugar along with a
few surrounding nucleotides.

The final correctional steps

are filling in the resulting void by DNA polymerase and
sealing the new bases in by DNA ligase (97,98).
After generation of these environmentally propagated
bulky DNA lesions, the repair mechanism routinely employed
in humans (as we do not have DNA photolyase homologues) is
nucleotide excision repair (NER) (92).

Xeroderma

pigmentosum patients are acutely susceptible to these
insults due to mutations in components of the NER system
(99).

NER entails the recruitment of several factors such

16

as DDB1 and DDB2 (a NRMT1 target), coordinated by PARP1,
nucleolytic excision of the lesion and immediately
surrounding DNA, which is filled in by DNA polymerase
(100).
Damage by chemical mutagens usually falls under one of
two broad categories: point mutations or indel mutations
(described above) (92).

Point mutations are the

replacement of a base with a different base; these
mutations are sub-divided into transitions and
transversions.

A transition mutation is the replacement of

a purine (or pyrimidine) base with another purine (or
pyrimidine) base (e.g. adenine for guanine, or thymine for
cytosine).

A transversion mutation, however, is the

replacement of a purine (or pyrimidine) base for a
pyrimidine (or purine) base (e.g. guanine for cytosine).
DNA intercalating agents can create indel mutations.
Ethidium bromide is one such common intercalating agent,
and it is frequently used to visualize DNA in gel
electrophoresis.

The local distortion caused by the

incorporation of the intercalating agent often leads to the
insertion or deletion of a nucleotide during replication
(92,101).
In addition to these point mutation base swaps,
reactive oxygen species (ROS) can oxidize bases.
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Guanine

is commonly oxidized to 8-oxoguanine, which can pair with
cytosine or adenine, leading to a point mutation
transversion from G • C à T • A (92).
All forms of DNA repair discussed thus far are
mechanisms mobilized for single strand mutations and
lesions.

DNA double-strand breaks (DSBs) are rectified by

nonhomologous end-joining (NHEJ) or homologous
recombination (92).

The homologous proteins Ku70 and Ku80

detect DSBs in eukaryotes (92,102).

In NHEJ, the broken

DNA strands must be realigned, facilitated by Ku70 and Ku80
(92).

After the strands have been realigned, nucleotides

must be either removed by nucleases or filled in by DNA
polymerase.
ligase.

Finally, the strands will be ligated by DNA

NHEJ is not a perfect solution, as nucleolytic

removal causes mutations (92).
Homologous recombination is an important step in
meiosis.

As a repair mechanism, recombination can repair

DSBs through homologous end-joining.

In this process, the

normal, undamaged sister chromatid serves as the repair
template (103).

Holliday junctions are formed, which

involves the Rad51 protein, and the broken DNA strands
intersect each other in these junctions.

Following this

intersection, DNA polymerase closes the breakage points,
which is sealed by DNA ligase (92).
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Unlike NHEJ,

homologous end-joining is not error-prone and does not
result in mutations because it uses the correct and intact
sister chromatid as the template for repair (103).
Moreover, homologous recombination can also be used to
correct an impaired replication fork (92).

SET DOMAINS AND EZH2

As methylation governs such diverse processes,
altering methylation levels, or the degree of methylation,
can be deleterious.

Recent work demonstrated that a subset

of B-cell lymphoma patients has mutations in the H3K27
methyltransferase EZH2 – the catalytic component of the
polycomb repressive complex 2 (PRC2) (104,105).

These

mutations occur in aromatic residues in a region
surrounding the active site known as the aromatic cage, and
many of these residues are conserved in the majority of
methyltransferases (105).

EZH2 contains the evolutionarily

conserved SET domain, which is a catalytic domain of
approximately 130 residues found in the majority of
methyltransferases (106).
One important feature of the SET domain is the lysine
access channel.

This connects the sites of cofactor

binding as well as substrate binding (106,107).
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Several

aromatic amino acids comprise this region, and the size of
the channel resolves whether the methyltransferase can
mono-, di-, or trimethylate substrates, or any combination
of the three states (106,107).

Noteworthy

methyltransferase exceptions which do not contain a SET
domain include the H3K79 methyltransferase DOT1L, as well
as NRMT1 and NRMT2.

NRMT1 and NRMT2 are Class I Rossmann-

like fold methyltransferases (108-110).
EZH2 is crucial for proliferation and has been
implicated in cancer for years (105,111-114).

A handful of

mutations of an evolutionarily conserved tyrosine residue
within the SET domain of EZH2, Y641, were found in patient
samples, including Y641F and Y641N (105).

These mutations,

as well as Y641C studied by another group (115), result in
a shift in the H3K27 methylation pattern, promoting
primarily trimethylation over monomethylation (105).

As

the aromatic cage determines the catalytic specificity of
EZH2, the Y641 mutation changes the size of its aromatic
cage, and thus its catalytic specificity (105).

From that

study, mutant EZH2 had the highest in vitro enzymatic
activity on dimethylated H3K27 peptide substrate (forming
trimethylated H3K27 peptide substrate), while for wild type
(WT), the enzymatic activity was lowest (105).

Besides the

resultant shift in methylation state, transcriptional
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profiles were found to be altered, with ensuing effects
such as increased proliferation and colony formation
(anchorage-independent growth) (105,111).

NRMT AND RCC1

My work focuses on the homologous N-terminal
methyltransferases NRMT1 (N-terminal regulator of chromatin
condensation methyltransferase 1) and NRMT2 (N-terminal
regulator of chromatin condensation methyltransferase 2).
Following cleavage of the initiator methionine on target
proteins, NRMT1 and NRMT2 methylate the α-amine of the
subsequent N-terminal residue (46,47).

They differ in

catalytic specificity in that NRMT2 is only a
monomethylase, while NRMT1 is a distributive trimethylase,
capable of performing all three states of methylation
(46,47).

Since NRMT1 is a distributive trimethylase, it

binds its substrate and adds one methyl group at a time,
dissociating from the substrate after the addition of each
methyl group (46).

Being a monomethylase, NRMT2 aids in

this process by adding the first methyl group to the
substrate, resulting in substrates that can be more quickly
trimethylated by NRMT1 (46).
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NRMT1 (also known as METTL11A, or NTMT1) and NRMT2
(also known as METTL11B) are 25-kD and 32-kD, respectively.
They share 50% sequence identity and 75% sequence
similarity (44,46) (Fig. 1).

In addition, their substrates

possess an N-terminal X-P-(K/R) consensus sequence.

X can

be any amino acid other than tryptophan, isoleucine,
leucine, aspartate, or glutamate (46).

P is typically any

polar or nonpolar amino acid (no charged amino acids), and
lysine or arginine is accepted in the third position (44).
Based on the NRMT consensus sequence, it was predicted
that these methyltransferases target over 300 substrates
(44,50).

A handful of these putative substrates have been

identified and experimentally verified, including the
following: RCC1 (regulator of chromatin condensation 1),
Rb, SET, PARP3 [poly(ADP-ribose) polymerase 3], CENP-A
(centromere protein A) (116), CENP-B (centromere protein
B), DDB2 (damaged DNA-binding protein 2), KLHL31 (kelchlike protein 31), RPL23A (ribosomal protein L23a), and MYL3
(myosin light polypeptide 3) (20,46,47,50,52,117-119).
RCC1 is a 45-kD protein, and the first identified
substrate to be N-terminally methylated by NRMT1 (47).

It

is the only identified guanine-nucleotide exchange factor
for the Ran GTPase, and is vital for cytoplasmic-nuclear
transport, nuclear envelope development, mitosis and
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Figure 1. Protein sequence alignment of human NRMT1 and
NRMT2.
Sequence alignment shown for NRMT1 and truncated NRMT2
(NRMT2 shown without the flexible N-terminal domain not
found in NRMT1).

The amino acid sequences of NRMT1 and

NRMT2 are 50% identical and 75% similar.

Identical

residues are highlighted in black, and similar residues are
highlighted in gray.
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mitotic spindle assembly, and chromatin association through
binding DNA and histones H2A and H2B (120-125).
Nuclear localization of RCC1 is crucial for
interphase, and the N-terminal methylation of RCC1 is
essential for its association with chromatin, as well as
proper mitotic function and mitotic spindle formation
(47,120,121).

This is evidenced by data showing that the

loss of NRMT1 (loss of RCC1 methylation), or the presence
of methylation-defective RCC1 mutants, causes reduced
chromatin association of RCC1 (decreased DNA binding)
during mitosis, giving rise to an abnormal multi-spindle
phenotype (as opposed to normal bipolar spindle formation
in mitosis) (47,120).
As stated before, unlike EZH2, NRMT1 and NRMT2 do not
harbor SET domains (108-110).

Importantly though, the

aromatic cage residues of NRMT1 and NRMT2 are conserved
with respect to EZH2.

Given this, I hypothesized that the

shape and size of their aromatic cages may similarly
dictate the catalytic specificities of NRMT1 and NRMT2.
Likewise, I postulated that mutation of these aromatic cage
residues in NRMT1 and NRMT2 can therefore alter their
catalytic specificities.
It has also been shown that NRMT1 depletion results in
oncogenic phenotypes such as increased proliferation, cell
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invasion and migration, and an increased sensitivity to DNA
damaging agents (50,51).

These phenotypes suggest that

monomethylation by NRMT2 alone is insufficient to
functionally compensate for the loss of trimethylation
(50,51).
Importantly, mutations of both NRMT1 and NRMT2 are
found in numerous human cancers (COSMIC, Catalogue of
Somatic Mutations in Cancer database), and I was interested
in determining if any of these mutations result in a
shifted degree of N-terminal methylation, similar to the
EZH2 mutations.

I therefore hypothesized that mutations in

or around these aromatic residues in NRMT1 and NRMT2 would
shift the degree of N-terminal methylation via altered
catalytic specificity.

This hypothesis is addressed by aim

1, or Chapter II.
Determining which cancer mutations shift the levels of
N-terminal methylation will help to determine their
importance to oncogenicity.

Biochemical characterization

of the mutations is therefore the first step towards that
goal.

Studying mutations of the conserved aromatic cage

residues can also tell us whether these residues, or an
alternate structural motif, contribute to the catalytic
specificity of NRMT1 and NRMT2.
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As previously mentioned, the loss of NRMT1 results in
oncogenic phenotypes such as increased proliferation, cell
invasion and migration, anchorage-independent growth, as
well as an increased sensitivity to DNA damaging agents
(50,51).

NRMT1 must therefore be crucial for survival, or

repair, in response to DNA damage.

NRMT1 knockout mice

also exhibit premature aging phenotypes, formation of
necrotic livers and polycystic ovaries, altered metabolism,
and their MEFs (mouse embryonic fibroblasts) manifest an
increased sensitivity to oxidative damage (51).
I was thus interested in determining the degree of Nterminal methylation conferred by mutations of NRMT1 and
NRMT2, which is detailed in Chapter II.

Given the

sensitivity of NRMT1-depleted cells to DNA damaging agents,
I hypothesized that altered N-terminal methylation patterns
would have an impact on cellular proliferation, as well as
the DNA damage response.

This hypothesis is addressed by

aim 2, or Chapter III.
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CHAPTER II: SELECT HUMAN CANCER MUTANTS OF NRMT1 ALTER ITS
CATALYTIC ACTIVITY AND DECREASE N-TERMINAL TRIMETHYLATION
(109)

BACKGROUND

Lysine methylation is an important posttranslational
modification (PTM) for regulating protein function.

This

PTM plays crucial roles in chromatin organization, DNA
repair, and transcriptional regulation (48,49).

The ε-amino

groups of lysine side chains can be mono-, di-, and
trimethylated, and each methylation state has a distinct
functional readout, dependent upon the residue methylated
(22,48,53-56).

These functional readouts are generally

accomplished by reader proteins, which contain PTM-specific
recognition domains (64,76,77).

Readers binding to

methyllysine commonly have chromatin organization modifier
domains (chromodomains), but can also contain Tudor, MBT,
PWWP, PHD finger domains or Ankyrin or WD repeats (126).
These methyllysine binding domains are specific for
distinct lysine residues and distinct methylation states
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(mono-, di-, or tri-) (127).

Recognition of methylated

lysines by methyllysine readers leads to recruitment of
protein complexes, such as chromatin-remodeling complexes,
transcriptional machinery, or DNA repair holoenzymes
(22,24,53-55).
As methylation governs such diverse processes,
altering methylation levels, or the degree of methylation,
can be deleterious.

Recent work demonstrated that a subset

of B-cell lymphoma patients have dominant mutations in the
histone H3 lysine 27 (H3K27) methyltransferase EZH2, the
catalytic component of the polycomb repressive complex 2
(PRC2) (104,105).

These mutations occur in residues that

create an aromatic cage in the active site and are
conserved in the majority of methyltransferases (105).

One

of the most commonly mutated residues in EZH2 is tyrosine
641 (Y641) (105).

Mutation of this tyrosine to

phenylalanine (Y641F) or asparagine (Y641N) shifted the
H3K27 methylation pattern, promoting trimethylation over
monomethylation (105).

The dominant Y641 mutations changed

the size of the EZH2 aromatic cage, and thus altered its
catalytic specificity (105).

As a result of the shift in

methylation state, transcriptional profiles were altered,
and cellular proliferation rates and colony formation
ability increased (105,111).
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N-terminal methylation of the free α-amino group is
another type of protein methylation, and it has been
established as a regulator of protein-DNA interactions
(120).

Loss of N-terminal methylation of regulator of

chromatin condensation 1 (RCC1) results in its
mislocalization from chromatin and multi-polar spindle
formation, (120) while loss of N-terminal methylation of
the DNA repair protein DNA-binding protein 2 (DDB2) impairs
its recruitment to damaged DNA, and subsequently,
nucleotide excision repair (NER) (52).
My work focuses on the homologous N-terminal
methyltransferases NRMT1 (N-terminal RCC1 methyltransferase
1) and NRMT2 (N-terminal RCC1 methyltransferase 2).
Following cleavage of the initiating methionine, they
methylate the α-amine of the first N-terminal residue of
their targets (46,128).

They differ in catalytic

specificity in that NRMT2 is a monomethylase, and NRMT1 is
a trimethylase (46,128).

NRMT1 is a distributive

trimethylase, as it binds its substrate and adds one methyl
group at a time, dissociating from the substrate after the
addition of each methyl group (46).

NRMT2 primes

substrates with the first methyl group, thereby increasing
trimethylation rates of NRMT1 (46).

NRMT1 and NRMT2 are

50% identical and 75% similar and share an N-terminal X-P-K
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consensus sequence (44,46).

Based on this consensus

sequence, it is predicted that these methyltransferases
target over 300 substrates in humans (44).
Y641 of EZH2 aligns with similar tyrosines in the
active sites of other methyltransferases, including G9a and
SETD7, and confers trimethylase activity to both these
methyltransferases when mutated to phenylalanine or alanine
(62,107).

The corresponding aromatic residues in NRMT1 and

NRMT2 are Y19 and F75, respectively (46).

Given that

mutation of tyrosine to phenylalanine has been shown to
change catalytic specificity, (105) I hypothesized these
aromatic residues were responsible for the differing
catalytic activities of NRMT1 and NRMT2.

In addition to

Y19 and F75, the active sites of NRMT1 and NRMT2 have
differing aromatic residues at positions W20 and Y76,
respectively (46).

I also tested the effect of these

residues on the catalytic specificities of NRMT1 and NRMT2.
Lastly, both NRMT1 and NRMT2 mutations are found in
human cancers (Cosmic Catalogue of Somatic Mutations in
Cancer;
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/).
While mutations of Y19 or F75 have yet to be identified, I
tested whether other mutations nearby (NRMT1 Q144H - lung
cancer) or in the adjacent peptide-binding channel (NRMT1
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N209I - endometrial cancer; NRMT1 P211S - lung cancer; and
NRMT2 V224L - breast cancer) alter catalytic activity
(Cosmic Catalogue of Somatic Mutations in Cancer).
It has been shown that loss of NRMT1 results in
oncogenic phenotypes such as increased proliferation, cell
invasion and migration, and an increased sensitivity to DNA
damaging agents (50,51).

These phenotypes suggest that

methylation by NRMT2 alone is insufficient to functionally
compensate for the loss of trimethylation, (50,51) and
indicates a decrease in NRMT1 trimethylase activity will
result in similar oncogenic phenotypes.

Determining which

cancer mutations alter the levels of N-terminal methylation
can help to determine their role in promoting tumor
progression and also provide a marker for tumors more
sensitive to DNA damaging agents.

Studying mutations in

the conserved aromatic residues of the active site will
also tell us whether these residues can universally control
catalytic specificity or if alternate structural motifs
contribute to the catalytic specificity of NRMT1 and NRMT2.
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MATERIALS AND METHODS

Constructs and Antibodies

To make His6-tagged recombinant protein, the human
NRMT1 and NRMT2 ORFs (GE Dharmacon, Marlborough, MA) were
amplified to introduce a 5’ NdeI restriction site and a 3’
XhoI restriction site, and subcloned into pET15b vector
(EMD Millipore, Billerica, MA).

These were used as

templates for constructing all subsequent NRMT1 and NRMT2
mutants using the Quikchange site-directed mutagenesis
protocol (Agilent Technologies, Santa Clara, CA).

The

following forward primers and their reverse complements
were used:
Y19F: 5’-CCAAGGCCAAGACCTTCTGGAAACAAATCCCAC-3’
W20Y: 5’-CCAAGGCCAAGACCTACTACAAACAAATCCCACCC-3’
Q144H: 5’-GCCACCTCACCGATCACCACCTGGCCGAGTTC-3’
N209I: 5’-GAGGAGAGGCAGGAGATCCTCCCCGATGAGATC-3’
P211S: 5’-GGCAGGAGAACCTCTCCGATGAGATCTACC-3’
F75Y: 5’-GCCAGAGCTAAACTTTACTACCAAGAAGTACCAGC-3’
Y76W: 5’-GCCAGAGCTAAACTTTTCTGGCAAGAAGTACCAGCCAC-3’
V224L: 5’-CATATTGAAGGACAATCTGGCCCGGGAGGGCTGTATC-3’
All His6 proteins were purified as previously described
(129).
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Primary antibodies used for western blots are as
follows: 1:5000 polyclonal rabbit anti-me1/2RCC1 (mono/dimethylated SPK-RCC1) (120), 1:10,000 polyclonal rabbit
anti-me3RCC1 (trimethylated SPK-RCC1) (120), 1:1000
polyclonal goat anti-RCC1 (Santa Cruz Biotechnology, sc1162, Santa Cruz, CA), 1:2000 polyclonal rabbit anti-NRMT1
(128), 1:3000 polyclonal rabbit anti-GAPDH (Trevigen,
Gaithersburg, MD), and 1:1000 monoclonal mouse antipolyHistidine (Sigma Aldrich, St. Louis, MO). 1:1000
polyclonal rabbit anti-Mettl11a/NRMT1 (Abcam, Cambridge,
United Kingdom) was used to detect WT and mutant NRMT1
(Fig. 9) as the NRMT1 antibody created by the lab
recognizes an epitope containing N209 and P211.

Secondary

donkey anti-rabbit, anti-mouse, and anti-goat HRP
antibodies were used.

For western blots, 10%

polyacrylamide gels and tris-glycine separation were used;
proteins were transferred to nitrocellulose membranes,
which were blocked using 5% nonfat dry milk in TBST (200 mM
Tris, 1.37 M NaCl, 0.05% Tween-20; pH 7.5).

In Vitro Methylation Assays

All methylation assays were conducted at 30 °C using 1
μg recombinant enzyme (full-length protein), 0.5 μg
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recombinant RCC1 substrate (full-length protein), and 100 μM
AdoMet unless otherwise noted.

The reaction volume was

adjusted to 50 μl with methyltransferase buffer (50 mM
potassium acetate, 50 mM Tris/HCl, pH 8), and reactions
were run for one hour.

Methylation assays using varied

RCC1 concentration were conducted using 1 μg recombinant
enzyme, 0.1-2 μg recombinant RCC1 substrate, and 100 μM
AdoMet.

The reaction volume and time were unchanged.

Methylation assays conducted at varying times used 1 μg
recombinant enzyme, 0.5 μg recombinant RCC1 substrate, and
100 μM AdoMet.

The reaction volume was unchanged, but

reactions were run for 30 minutes to 3 hours.

Methylation

assays were visualized by western blot analysis, except for
mass spectrometry samples.

Samples were prepared for MS

analysis by performing a methyltransferase assay using 1 μg
recombinant enzyme, 0.5 μg recombinant RCC1 substrate, and
100 μM AdoMet.

Reaction volume was adjusted to 20 μl with

methyltransferase buffer, and reactions were run for one
hour at 30 °C.

Reactions were run on an SDS/PAGE gel, and

bands visualized by Coomassie Blue stain.

The analysis for

the presence and extent of RCC1 N-terminal methylation by
MS was conducted as previously described (46).
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Cell Culture

A549 human lung carcinoma cells (ATCC) were maintained
in Dulbecco’s Modified Eagle Medium (DMEM) (Life
Technologies, Grand Island, NY) with 10% fetal bovine serum
(FBS) (Atlanta Biologicals, Atlanta, GA) and 1% penicillinstreptomycin (P/S) (Life Technologies).

HCT116 human

colorectal carcinoma cells lines (a generous gift from Dr.
Ian Macara, Vanderbilt University) were maintained in
McCoy’s 5a Modified Medium with 10% FBS and 1% P/S.
HEK293LT human embryonic kidney cells (also a generous gift
from Dr. Ian Macara) were grown in DMEM with 10% FBS and 1%
P/S.

Generation of NRMT1 CRISPR/Cas9 Knockout Cell Line

Suitable CRISPR/Cas9 target sites in the human NRMT1
gene were identified using an online CRISPR Design Tool
(http://tools.genome-engineering.org) (130).

A target site

in the first exon (Fig. 10) was chosen and the following
oligos designed and ordered from Integrated DNA
Technologies (IDT, Coralville, IA).
Top: 5’- CACCGACGGTGGACGGCATGCTTGG - 3’
Bottom: 5’- AAACCCAAGCATGCCGTCCACCGTC- 3’
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The oligos were annealed, phosphorylated, and subcloned
into BbsI-digested pSpCas9(BB)-2A-Puro (Addgene, Cambridge,
MA) as previously described (130).
verified by DNA sequencing.

Resulting clones were

6 x 105 HCT116 cells were

transfected with 250 ng either empty pSpCas9(BB)-2A-Puro or
the same vector containing the NRMT1 target sequence.

48

hours post-transfections, cells were treated with 2 µg/ml
puromycin for three days.

Surviving cells were transferred

to individual wells in a 96-well plate.
expanded and passaged.

Cells were

Half were used to make carry plates

the other half were used to isolate genomic DNA.

For the

first six wells, the genomic DNA was PCR amplified with
primers flanking the target sequence.

The resultant PCR

products were sequenced at the University of Louisville
Genomics Core.

All six clones contained frameshift

mutations and were selected for expansion, and analyzed for
NRMT1 expression and N-terminal methylation by western blot
(Fig. 10).

Subclone #6 was used in all subsequent

experiments.

Lentivirus Production

Wild type (WT), N209I, or P211S human NRMT1 were
amplified from the pet15b vector to introduce a 5’ PmeI
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restriction site and a 3’ PmeI restriction site, and
subcloned into pWPI lentiviral expression vector (Addgene).
GFP-tagged lentivirus expressing WT NRMT1, N209I NRMT1, or
P211S NRMT1 were made by co-transfecting HEK293LT cells
with 50 µg pWPI containing the appropriate NRMT1 cDNA, 37.5
µg psPAX2 packaging vector, and 15 µg pMD2.G envelope
plasmid using calcium phosphate transfection.

48 hours

post-transfection, viral supernatants were collected,
concentrated with 100K ultrafilters (EMD Millipore), and
titered in the HEK293LT cells.

A549, HCT116, or HCT116

NRMT1 KO cells were infected with virus to a multiplicity
of infection (MOI) of 1.

Calculations performed to

estimate MOI are based on the detection of GFP-positive
cells by microscopy, and the dilution of virus necessary to
achieve this.

Three days post-transduction, cells were

counted and used in cell growth assays; remaining cells
were used for western blot analysis.

Cell Growth Assays

One thousand control A549, HCT116, HCT116 NRMT1 KO, or
HCT116 pSpCas9 cells were plated in triplicate in a 96-well
plate in 100 µl of the appropriate cell culture media.
Concurrently, A549, HCT116, or HCT116 NRMT1 KO cells
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transduced with WT, N209I, or P211S NRMT1-expressing virus
were plated in triplicate in 96-well plates.
triplicates for each condition were made.

Five sets of

On the day of

plating (day 0), 20 µl of Aqueous One Solution (Promega,
Madison, WI) (CellTiter 96â AQueous One Solution Cell
Proliferation Assay) was added to the first set of
triplicates for each condition and the absorbance at 490 nm
was read after two hours.

Readings were taken on day 0 and

daily for four additional days.

Relative fold increase was

calculated by dividing average absorbance on each day by
average absorbance at day 0.
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RESULTS

Aromatic Cage Mutants Do Not Exhibit Altered Methylation
Patterns

Y19 is the NRMT1 tyrosine residue that most closely
aligns with the position of Y641 in the methyltransferase
active site of EZH2.
F75.

In NRMT2, this residue is replaced by

As mutation of EZH2 Y641 to phenylalanine switches

its catalytic activity, I hypothesized this amino acid
substitution between NRMT1 and NRMT2 might be the cause of
their differing catalytic activities.

To test this

hypothesis, recombinant proteins were made for NRMT1 Y19F
and NRMT2 F75Y, and their ability to mono-, di-, or
trimethylate full-length recombinant RCC1 over one hour was
assayed by western blot.

Unexpectedly, neither mutation

significantly affected methyltransferase activity (Fig.
2A,B; Fig. 3A,B).

Similar to wild type (WT) NRMT1, NRMT1

Y19F exhibited only trimethylase activity (Fig. 2A,B).
Similar to WT NRMT2, NRMT2 F75Y exhibited only
monomethylase activity (Fig. 3A,B).
In addition to an inability to switch catalytic
activities, these mutations also did not significantly
alter total methylation levels (Fig. 2C,D; Fig. 3C).
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Figure 2. N-terminal methylation patterns of wild type and
mutant NRMT1.
The directed mutation of aromatic residues Y19 and W20 in
NRMT1 and the Q144H mutation found in human lung cancer
showed no effects on (A) monomethylation/dimethylation
(me1/2RCC1) or (B) trimethylation (me3RCC1) levels.
However, the NRMT1 mutants N209I (endometrial cancer) and
P211S (lung cancer) exhibit (A) increased
monomethylation/dimethylation of RCC1 and (B) decreased
trimethylation of RCC1 as compared to wild type (WT).
Total RCC1 is shown as loading control.
analysis of panel A.
intensity.

(C) Densitometry

Ratio of me1/2RCC1:Total RCC1 band

(D) Densitometry analysis of panel B.

Ratio of

me3RCC1:Total RCC1 band intensity, normalized to WT NRMT1.
Each data point represents the ± SEM of three independent
experiments.

* denotes P < 0.05, determined by an unpaired

two-tailed Student’s t-test.

Bands were quantified using

ImageJ software (NIH).
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Figure 3. N-terminal methylation patterns of wild type and
mutant NRMT2.
The directed mutation of aromatic residues F75 and Y76 in
NRMT2 showed no effect on (A) mono-/dimethylase activity
(B) but no corresponding increase in trimethylase activity.
The breast cancer mutation of V224 in NRMT2 showed a
significant decrease in (A) mono-/dimethylase activity (B)
but no corresponding increase in trimethylase activity.
Total RCC1 is shown as loading control.
analysis of panel A.

Ratio of me1/2RCC1:Total RCC1 band

intensity, normalized to WT NRMT2.
analysis of panel B.

(C) Densitometry

(D) Densitometry

Ratio of me3RCC1:Total RCC1 band

intensity, normalized to WT NRMT1.

As previously shown,

trimethylation levels are significantly different between
WT NRMT1 and WT NRMT2 (46), but none of the NRMT2 mutants
were significantly different from WT NRMT2.

Low levels of

trimethylation signal seen with WT NRMT2 are not due to
trimethylation activity but cross-reactivity of me3RCC1
antibody with lower levels of methylation when no
trimethylation is present (46,47).

Each data point

represents the mean ± SEM of three independent experiments.
* denotes P < 0.05, determined by an unpaired two-tailed
Student’s t-test.

Bands were quantified using ImageJ

software (NIH).
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is contrary to published data showing that the NRMT1 Y19F
mutation significantly inhibits the ability of WT
recombinant NRMT1 to methylate an N-terminal peptide of
CENP-A (131).

As my assay was done with full-length

recombinant RCC1 as substrate, it may be that
enzyme/substrate binding is enhanced by interactions with
the full protein and the interaction of Y19 with substrate
is more imperative for peptide substrates.
consensus sequence dependent.

It may also be

The CENP-A N-terminal

sequence is Gly-Pro-Arg (GPR), while the RCC1 N-terminal
sequence is Ser-Pro-Lys (SPK).

The recently solved crystal

structure of human NRMT1 bound to CENP-A N-terminal peptide
indicates the Arg residue in the CENP-A consensus sequence
forms hydrogen bonds and electrostatic interactions with
Y19 (131).

These interactions may differ with a lysine

residue and make Y19 less crucial for catalytic function.
As the mutations in Y19 and F75 did not significantly
alter the methyltransferase activities of NRMT1 and NRMT2,
I next mutated the other aromatic residue that differs
between their active sites.
Y76 in NRMT2 (46).

W20 in NRMT1 is replaced with

Full-length recombinant proteins were

made for NRMT1 W20Y and NRMT2 Y76W, and their ability to
mono-, di-, or trimethylate full-length recombinant RCC1
was assayed by western blot.

Again, neither mutation
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significantly affected methyltransferase activity (Fig.
2A,B; Fig. 3A,B).

This is also contrary to previous

published data showing the W20Y mutation of NRMT1
significantly diminishes its ability to methylate the Nterminal peptide of CENP-A, (131) and further indicates the
most important catalytic residues may differ depending on
substrate length or consensus sequence.
To differentiate between these two possibilities, site
directed mutagenesis was performed on the plasmid used to
make full-length recombinant RCC1.

GPR-RCC1 was made to

mimic the CENP-A consensus sequence on a full-length
protein, as well as Gly-Pro-Lys (GPK) and Ser-Pro-Arg
(SPR)-RCC1 to assess if the first or third amino acid is
more important.

Wild type SPK-RCC1, as well as all three

full-length RCC1 consensus sequence mutants (GPK, SPR, and
GPR) could be in vitro methylated by WT, Y19F, and W20Y
NRMT1 (Fig. 4 A-D), indicating that the impaired Y19F and
W20Y activity seen by Wu et al. (110) is not due to a
difference in the three amino acid consensus sequence.
To determine if the impaired activity resulted from
substrate length, the activity of Y19F and W20Y NRMT1 on a
peptide containing the first 15 amino acids of WT RCC1
(SPKRIAKRRSPPADA) was tested by Dr. John Tooley.
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Supplemental Fig. 1. Y19F and W20Y NRMT1 activity is not altered by changing the RCC1 consensus
sequence, but W20Y activity is lost when using peptide substrate. (A) Western blots showing wild type (WT),
Y19F, and W20Y NRMT1 all trimethylate WT (SPK) full-length recombinant RCC1 (me3RCC1). Mutation of
the RCC1 consensus sequence to (B) SPR, (C) GPK, or (D) GPR does not affect the ability of WT, Y19F, or
W20Y to trimethylate the full-length substrate. NRMT1 blots shown to confirm equal loading of enzyme.
(E) Dot blot showing W20Y trimethyl (me3RCC1) and mono/dimethyl (me1/2RCC1) activity is lost when the
substrate is switched to a wild type (SPK) RCC1 N-terminal peptide. Tri- or monomethylated RCC1 peptide is
shown as a postive control (Control).
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Figure 4. Y19F and W20Y NRMT1 activity is not altered by
changing the RCC1 consensus sequence, but W20Y activity is
lost when using peptide substrate.
(A) Western blots showing wild type (WT), Y19F, and W20Y
NRMT1 all trimethylate WT (SPK) full-length recombinant
RCC1 (me3RCC1).

Mutation of the RCC1 consensus sequence to

(B) SPR, (C) GPK, or (D) GPR does not affect the ability of
WT, Y19F, or W20Y to trimethylate the full-length
substrate.
enzyme.

NRMT1 blots shown to confirm equal loading of

(E) Dot blot showing W20Y trimethyl (me3RCC1) and

mono-/dimethyl (me1/2RCC1) activity is lost when the
substrate is switched to a wild type (SPK) RCC1 N-terminal
peptide.

Tri- or monomethylated RCC1 peptide is shown as a

positive control (Control).

Blots are representative

images of three independent experiments.

Work in this

figure was performed by John Tooley, State University of
New York at Buffalo.
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Interestingly, Y19F was still able to trimethylate the
peptide, while W20Y was not (Fig. 4E), indicating it is
possible for a recombinant enzyme to have different
activities towards full-length and peptide substrates with
the same consensus
sequence.

Mutations Found in Human Cancers Alter NRMT1 and NRMT2
Activities

Human cancer mutations of NRMT1 and NRMT2 were selected
from the Cosmic Catalogue of Somatic Mutations in Cancer
database based on their proximity to the active site or
peptide-binding channel.

For NRMT1, I selected Q144H (lung

cancer), N209I (endometrial cancer), and P211S (lung
cancer).

Both the N209I and P211S mutations are in the

peptide binding channel of NRMT1, (131) while the Q144H
mutation is adjacent to H140, a third aromatic residue in
the active site (46).

Unlike Y19 and W20, this histidine

is conserved between NRMT1 and NRMT2 (46).
selected V224L (breast cancer).

For NRMT2, I

This valine is analogous

to M169 in NRMT1, (46) which is directly adjacent to N168,
an amino acid that forms both hydrogen bonds and
electrostatic interactions with substrate (131,132).
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In vitro methylation assays with the full-length
recombinant mutants and full-length recombinant RCC1 as a
substrate, showed the Q144H lung cancer mutation exhibited
similar levels of mono-/dimethylation (Fig. 2A) and
trimethylation (Fig. 2B) as WT NRMT1.

In contrast, the

N209I endometrial and P211S lung cancer mutants displayed
significantly increased levels of mono-/dimethylation (Fig.
2A,C) and significantly decreased levels of trimethylation
(Fig. 2B,D) compared to WT NRMT1, indicating these
mutations in patients could decrease global N-terminal
methylation levels in favor of mono-/dimethylation.

As

seen with WT NRMT2, the NRMT2 V224L breast cancer mutation
exhibited no trimethylase activity (Fig. 3B), but it also
exhibited significantly decreased monomethylase activity as
compared to control (Fig. 3A and C).

This indicates

patients harboring this mutation would have lower levels of
priming activity by NRMT2 and potentially less
trimethylation by NRMT1 as a consequence (46).

Mass Spectrometry Verification of N209I and P211S Shifted
Methylation Activity

As the N-terminal mono-/dimethyl RCC1 antibody
(me1/2RCC1) that was created cannot discriminate between

50

mono- and dimethylation, mass spectrometry (MS) analysis
was used to determine if the N209I and P211S NRMT1 mutants
were capable of monomethylation, dimethylation, or both.
The results from the MS analysis (Fig. 5, Fig. 6A-J) showed
that, of the recombinant RCC1 that underwent successful
cleavage of the initiating methionine (a portion of
recombinant RCC1 fails to undergo this cleavage and is
unable to be methylated in vitro), 63% was trimethylated by
WT NRMT1 and the remaining 37% remained unmethylated (46).
This is consistent with previous results showing WT NRMT1
will almost completely trimethylate RCC1 after one hour in

vitro (46).
With the N209I mutation, unmethylated RCC1 levels
increased to 73%, while RCC1 trimethylation levels dropped
to 13%, dimethylation levels increased to 7% and
monomethylation levels increased to 6%.

With the P211S

mutant, unmethylated RCC1 levels also increased to 73%,
trimethylation was further decreased to 5%, dimethylation
increased to 13%, and monomethylation increased to 9%.
MS analysis is consistent with the western blot results,

The

indicating these mutants exhibit decreased trimethylase
activity and increased mono- and dimethylase activity.
They also indicate, that unlike the EZH2 mutants which
switch catalytic activity from a monomethylase to
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Figure 5. Mass spectrometry analysis of WT and mutant
NRMT1.
Of the recombinant RCC1 with cleavage of the initiating
methionine, 63% was N-terminally trimethylated by
recombinant WT NRMT1. The remaining 37% remained
unmethylated. With the N209I mutation, unmethylated RCC1
levels increased to 73%, while RCC1 trimethylation levels
dropped to 13%, dimethylation levels increased to 7%, and
monomethylation levels increased to 6%. With the P211S
mutant, unmethylated RCC1 levels also increased to 73%,
trimethylation was further decreased to 5%, dimethylation
increased to 13%, and monomethylation increased to 9%.

I

prepared the graph contained in this figure, but the mass
spectrometry analysis was performed by the University of
Louisville Mass Spectrometry Core Laboratory and represents
one independent experiment.
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A. Peptide: SPKRIAKRRSPPA

Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\WT_SchanerTooley_150428.raw #746 RT: 12.78
ITMS, ETD@44.00, z=+3, Mono m/z=488.63516 Da, MH+=1463.89093 Da, Match Tol.=1.2 Da
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from: D:\Data\C.SchanerTooley\150428_SchanerTooley\WT_SchanerTooley_150428.raw
#1450 RT: 20.93
B.Extracted
Peptide:
SPKRIAKRRSPPA, S1-Trimethyl
ITMS, ETD@33.00, z=+4, Mono m/z=377.24014 Da, MH+=1505.93874 Da, Match Tol.=1.2 Da
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Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\N209I_SchanerTooley_150428.raw #731 RT: 12.01
ITMS, ETD@44.00, z=+3, Mono m/z=488.63538 Da, MH+=1463.89157 Da, Match Tol.=1.2 Da

C. Peptide: SPKRIAKRRSPPA
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D. Peptide: SPKRIAKRRSPPA, S1-Methyl (14.01564 Da)

Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\N209I_SchanerTooley_150428.raw #577 RT: 10.16
ITMS, ETD@33.00, z=+4, Mono m/z=370.23248 Da, MH+=1477.90810 Da, Match Tol.=1.2 Da
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Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\N209I_SchanerTooley_150428.raw #726 RT: 11.95
ITMS, ETD@44.00, z=+3, Mono m/z=497.96649 Da, MH+=1491.88492 Da, Match Tol.=1.2 Da

E. Peptide: SPKRIAKRRSPPA, S1-Dimethyl (28.03130 Da)
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632.39779
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R
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576.35966

1135.69333

568.35030

1137.70898
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1419.90199

710.45463
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A
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76.05189

38.52958

1
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F.
Peptide:
SPKRIAKRRSPPA, S1-Trimethyl#712 RT: 11.82
Extracted
from: D:\Data\C.SchanerTooley\150428_SchanerTooley\N209I_SchanerTooley_150428.raw
ITMS, ETD@33.00, z=+4, Mono m/z=377.23114 Da, MH+=1505.90273 Da, Match Tol.=1.2 Da
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z+2⁺#

1376.85979

688.93353
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1279.80702

640.40715

427.27386

1360.84107

680.92417

454.28521

1362.85672
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421.93428

1265.80395

633.40561
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R
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576.35966
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A

882.52686
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1135.69333
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379.23596
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332.54183

979.59221

490.29974

327.20225
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868.52379

434.76553
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811.48974
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406.24851
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795.47102
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399.24697
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332.89783
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446.29314
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268.14178

134.57453

90.05211
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135.58235

90.72399

12
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3
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G. Peptide: SPKRIAKRRSPPA

Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\P211S_SchanerTooley_150428.raw #719 RT: 11.55
ITMS, ETD@44.00, z=+3, Mono m/z=488.63657 Da, MH+=1463.89515 Da, Match Tol.=1.2 Da
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H. Peptide: SPKRIAKRRSPPA, S1-Methyl (14.01564 Da)

Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\P211S_SchanerTooley_150428.raw #617 RT: 10.16
ITMS, ETD@33.00, z=+4, Mono m/z=370.23251 Da, MH+=1477.90822 Da, Match Tol.=1.2 Da
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680.92417

454.28521

1362.85672

681.93200

454.95709 12

3

344.22925

172.61826

115.41460
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1279.80702

640.40715

427.27386

1263.78830

632.39779

421.93428

1265.80395

633.40561

422.60617 11
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1135.69333

568.35030

379.23596

1137.70898

569.35813
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327.20225
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866.50814

433.75771

289.50756

868.52379

434.76553

290.17945
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406.24851
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90.05211
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135.58235

90.72399
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I. Peptide: SPKRIAKRRSPPA, S1-Dimethyl (28.03130 Da)

Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\P211S_SchanerTooley_150428.raw #615 RT: 10.14
ITMS, ETD@33.00, z=+4, Mono m/z=373.73621 Da, MH+=1491.92299 Da, Match Tol.=1.2 Da
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67.05222

2

230.14993

115.57860
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P

1376.85979

688.93353

459.62478

1360.84107

680.92417

454.28521

1362.85672

681.93200

454.95709 12

3

358.24490

179.62609

120.08648

K

1279.80702

640.40715

427.27386

1263.78830

632.39779

421.93428

1265.80395

633.40561

422.60617 11

4

514.34602

257.67665

172.12019

R

1151.71205

576.35966

384.57553

1135.69333

568.35030

379.23596

1137.70898

569.35813

379.90784 10

5

627.43009

314.21868

209.81488

I
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332.54183
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981.60786
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868.52379
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290.17945
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413.78473
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K
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406.24851
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795.47102

398.23915

265.82852

797.48667

399.24697

266.50041

7

8

982.66330

491.83529
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R

683.39477

342.20102

228.46977
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223.13020

669.39170

335.19949

223.80208

6

9

1138.76442

569.88585

380.25966
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171.09649
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119.73467
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P

284.16050

142.58389

95.39168

268.14178
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38.52958

26.02215

1

13

c²⁺#

c³⁺#

Seq.#

y⁺#

z⁺#

z+2²⁺#

z+2³⁺#

45.03724 S-Dimethyl

#2#
13

62

J.Extracted
Peptide:
SPKRIAKRRSPPA, S1-Trimethyl#731 RT: 11.71
from: D:\Data\C.SchanerTooley\150428_SchanerTooley\P211S_SchanerTooley_150428.raw
ITMS, ETD@33.00, z=+4, Mono m/z=377.23132 Da, MH+=1505.90346 Da, Match Tol.=1.2 Da

Intensity [counts]
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680.92417
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1362.85672
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454.95709 12

3
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186.63391

124.75837

K
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640.40715

427.27386

1263.78830

632.39779

421.93428

1265.80395

633.40561

422.60617 11
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528.36167

264.68447

176.79207

R
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Figure 6. ETD MS/MS spectra and sequence coverage of a-Nterminal peptides from recombinant RCC1 methylated by WT
NRMT1, N209I, or P211S.
WT NRMT1 produced (A) 37% unmethylated and (B) 63%
trimethylated RCC1.

N209I produced (C) 73% unmethylated,

(D) 6% monomethylated, (E) 7% dimethylated, and (F) 13%
trimethylated RCC1.

P211S produced (G) 73% unmethylated,

(H) 9% monomethylated, (I) 13% dimethylated, and (J) 5%
trimethylated RCC1.

All spectra were acquired and searched

using Mascot (v1.30).

c ; y ; z ; z + 2 fragments were

used for searching and the match tolerance was 1.2 Da.
Bolded red indicates observed c-ion fragment.
indicates observed y- or z-ion fragment.

Bolded blue

Raw data shown in

this figure was generated by the University of Louisville
Mass Spectrometry Core Laboratory and represents one
independent experiment.
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a trimethylase, the NRMT1 mutations are decreasing the
overall efficiency of the enzyme and preventing it from
both converting unmodified substrate to monomethylated and
monomethylated substrate to trimethylated.

NRMT1 Cancer Mutants Remain Distributive Methyltransferases

It was previously shown that NRMT1 works as a
distributive enzyme, first monomethylating its substrate,
then dissociating and reattaching for each subsequent
methylation step (46).

Richardson et al. confirmed this

distributive nature of NRMT1 and additionally showed it is
working through a random sequential bi-bi mechanism (133).
It was also shown that for the human RCC1 consensus
sequence (Ser-Pro-Lys), affinity of NRMT1 for substrate
increases with increasing substrate methylation levels,
(46) and it was hypothesized that this helps the enzyme to
quickly raise trimethylation levels without the
accumulation of mono- or dimethylated substrate.
In order to monitor if the N209I and P211S mutants were
impaired in the conversion of mono-/dimethylation to
trimethylation, I held enzyme and substrate concentrations
constant and varied the time of the in vitro methylation
reactions.

Western blot analysis showed that WT NRMT1,
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even at just 30 minutes, converted all mono-/dimethylation
to trimethylation (Fig. 7A).

While low levels of

trimethylation can be seen at 30 minutes with both the
N209I and P211S mutants, mono-/dimethylation levels are
higher and stay steady (N209I) or continue to increase
(P211S) up to 2 hours (Fig. 7B,C).

Finally, after 2 hours,

mono-/dimethylation levels begin to decrease with a
corresponding increase in trimethylation, indicating
conversion of one to the other (Fig. 7B,C).

These data

mirror the MS results (Fig. 5) and indicate that while
N209I and P211S are still distributive enzymes capable of
trimethylation, they are significantly slower at converting
mono- and dimethylation into trimethylation.
To assay whether the activity of the mutants could be
restored by a significant increase in substrate
concentration, I monitored the ability of the mutants to
mono-/dimethylate or trimethylate RCC1 at varying substrate
concentrations.

Western blot analysis of the in vitro

methylation assays revealed that N209I and P211S require a
higher substrate concentration to reach the trimethylation
levels seen with WT (Fig. 7D-F).

At low substrate levels

(0.25 µg), NRMT1 shows only trimethylated substrate (Fig.
7D), while neither mutation exhibits any methyltransferase
activity (Fig. 7E,F).

At 0.5 µg substrate, WT NRMT1
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Figure 7. Catalytic studies of WT and mutant NRMT1.
(A) WT NRMT1 fully trimethylates RCC1 (me3RCC1) in less
than 30 min, compared to (B) N209I and (C) P211S, which
exhibit primarily monomethylation/dimethylation (me1/2RCC1)
until 2h, where trimethylation levels begin to rise.

The

corresponding decrease in monomethylation/dimethylation is
evident only after 3h.

These data indicate N209I and P211S

are still distributive enzymes capable of trimethylation,
but they are slower at converting monomethylation to
trimethylation.

Total RCC1 is shown as a loading control.

Control (Cont.) reactions done without enzyme.

(D) At low

substrate levels, WT NRMT1 proceeds almost completely to
trimethylation.

As substrate concentration increases, the

levels of monomethylation/dimethylation by NRMT1 increase
because the ratio of unmodified substrate to previously
methylated substrate is higher.

(E-F) At low substrate

levels, the NRMT1 N209I and P211S mutants show no
methyltransferase activity.

As substrate concentration

increases, trimethylation begins to appear but does not
reach WT levels until a 1:1 molar ratio of enzyme to
substrate, indicating a higher substrate concentration is
needed for optimum trimethylase activity.
shown as a loading control for WT.

Anti-NRMT1 is

Anti-His is shown as a

loading control for mutant NRMT1, as this NRMT1 antibody
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recognizes an epitope containing N209 and P211 (47).

Blots

are representative images of three independent experiments.
Bands were quantified using ImageJ software (NIH) and
internally normalized to brightest band of each set, which
was set at 1.0.
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predominantly shows trimethylation (Fig. 7D), while both
mutants are just beginning to exhibit mono-/dimethylase
At 1.0 μg substrate, WT NRMT1 still

activity (Fig. 7E,F).

favors trimethylated product, while both N209I and P211S
still favor mono-/dimethylation (Fig. 7D-F).

It is not

until the molar amount of mutant enzyme equals the molar
amount of substrate (1 µg of NRMT = 40 pmol; 2 µg of RCC1 =
40 pmol) that the mutants have mono-/di- and trimethylation
levels comparable to WT NRMT1 (Fig 7D-F).

This indicates

the mutants require a higher substrate concentration to
reach maximal activity.

Molecular Modeling of N209I and P211S

The examination of the NRMT1 crystal structure (128)
showed N209I and P211S to be in the peptide-binding channel
near the aromatic residues (Y19, W20, H140) of the active
site (132).

NRMT1 is a class I methyltransferase

consisting of a seven-stranded b sheet surrounded by five ahelices (128).

In addition, there are three helices in the

N-terminus segment, a pair of b hairpins, and a series of
loops connecting the structural elements (131).

It has

been determined that the helices in the N-terminal segment
cluster with loop 4 (L4) and loop 67 (L67) to create the
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peptide-binding domain, which is integrated by residues
L31, Y34, I37, W136, L210, P211, I214, V217, Y215, and E213
(131).

While both N209 and P211 are in L67 (Fig. 8A),

neither was previously predicted to directly interact with
substrate (131).
To determine how the N209I and P211S mutations might
otherwise affect the peptide-binding channel, molecular
modeling was performed (134).

The modeling revealed that

P211 is oriented toward the peptide-binding channel, and
its mutation to serine could alter the shape of the cavity
itself (Fig. 8B).

Alternatively, prolines confer distinct

shapes to unstructured regions, so its mutation to serine
could change the configuration of L67 in an unpredictable
manner.

Mutation of N209 to isoleucine does not make any

visually obvious changes to the structure of the peptidebinding channel (Fig. 8B).

However, asparagine to

isoleucine mutations have previously been shown to affect
protein characteristics (135).

The amide group of

asparagine can hydrogen bond, while the isoleucine side
chain is hydrophobic and does not.

While these hydrogen

bonds might not be directly formed with substrate, they may
be necessary for proper orientation of L67.

Taken together,

I hypothesize that residues in the peptide-binding channel
that do not directly interact with the substrate can still
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A

L67

B

P211S

72

SAM

N209I

Figure 8. Molecular modeling of NRMT1 mutants.
(A) Full crystal structure of NRMT1.

Arrow denotes loop67

(L67, navy blue) where N209 and P211 are located.

The

methyltransferase co-factor S-adenosyl-methionine (SAM)
bound to the active site is indicated in gray.

(B) Model

comparing wild type NRMT1 (green, PDB code 2EX4) to mutated
NRMT1 (pink), as calculated by the Robetta server (136).
The schematic shows a zoomed in area of the active site.
Molecular modeling was performed by Janusz Petkowski,
Massachusetts Institute of Technology.
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regulate substrate binding by altering the overall
orientation of L67.

NRMT1 Mutations Do Not Act as Dominant Negatives in Cancer
Cells

It was determined that the EZH2 Y641 mutation acted in
a dominant manner by exogenously expressing both WT EZH2
and Y641F EZH2 in HEK293T cells, which already harbor WT
EZH2 activity, and monitoring H3K27me3 levels (105).

While

expression of WT EZH2 produced a barely detectable increase
in H3K27me3, expression of Y641F EZH2 resulted in a
significant increase in H3K27me3, (105) indicating even
with WT EZH2 present, the Y641F can change H3K27
methylation levels.

HEK293T cells expressing Y641F EZH2

were also more resistant to a small-molecule inhibitor of
single-carbon transfer methyltransferases (105).
To monitor if the P211S and N209I NRMT1 mutations
worked in a similar dominant fashion, both were exogenously
expressed using lentivirus at an MOI of 1 in A549 human
lung carcinoma cells (as P211S was originally found in a
lung cancer sample) (137).

Though expression levels of WT,

N209I, and P211S NRMT1 were similar, only WT NRMT1 showed a
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slight increase in N-terminal trimethylation levels (Fig.
9A).

Neither N209I nor P211S significantly changed either

mono-/di- or trimethylation levels of endogenous RCC1 (Fig.
9A), indicating they are not acting in a dominant negative
manner.

Expression of the mutants also did not

significantly affect cellular proliferation (Fig. 9B).
The role of NRMT1 in lung cancer remains unclear, though it
has been found to have slightly decreased expression in
non-small cell lung carcinoma (138).

NRMT1 is most

commonly found under-expressed in breast cancer,
glioblastoma, and leukemia (139-142).

It has been

correspondingly shown that in breast cancer NRMT1 is acting
as a tumor suppressor, and its loss promotes oncogenic
growth (50).

Conversely, NRMT1 has shown to be robustly

overexpressed in a variety of colon cancer samples, (143145) where I predict NRMT1 may be acting as an oncogene.
To monitor if the P211S and N209I mutations have a
differential effect in a cancer type that typically
overexpresses NRMT1, the same overexpression experiments
were performed in HCT116 human colorectal carcinoma cells.
As in A549 cells, neither expression of P211S nor N209I
were able to change mono-/di- or trimethylation levels of
endogenous RCC1 (Fig. 9C) or alter cellular proliferation
levels (Fig. 9D).
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Figure 9. NRMT1 mutants are not dominant negatives but
reduce N-terminal trimethylation when homozygous.
(A-D) When overexpressed in (A) A549 or (C) HCT116, neither
the N209I nor the P211S NRMT1 mutants (A,C) alter the level
of RCC1 N-terminal monomethylation/dimethylation
(me1/2RCC1) or trimethylation (me3RCC1) or (B,D) cellular
growth rates as compared to control cells expressing empty
vector (-) or cells overexpressing wild type (WT) NRMT1.
When expressed in HCT116 cells where NRMT1 expression has
been knocked out (KO) through CRISPR/Cas9 genome editing,
(E) neither the N209I nor P211S mutant can restore Nterminal trimethylation levels, and (F) P211S is also
unable to rescue the growth defect seen with NRMT1
knockout.

Each data point represents the mean ± SEM of

three independent experiments.

* denotes P < 0.05,

determined by a paired two-tailed Student’s t-test.
is shown as a loading control.

GAPDH

Anti-Mettl11a/NRMT1 (Abcam)

used to determine WT and mutant NRMT1 expression levels.
Blots are representative images of three independent
experiments.

Bands were quantified using ImageJ software

(NIH) and internally normalized to wild type untransfected
bands, which were set at 1.0.

Work in this figure was

performed by John Tooley, State University of New York at
Buffalo.
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A CRISPR/Cas9 HCT116 NRMT1 knockout strain was
recently made, which completely lacks NRMT1 expression and
N-terminal trimethylation, while maintaining wild type
mono-/dimethylation levels (Fig. 10 and Fig. 9E).

To test

if the P211S and N209I mutations could alter cellular
phenotypes as homozygous mutations, the NRMT1 knockout cell
lines were transduced with both mutations at an MOI of 1.
As opposed to rescue with WT NRMT1, neither mutation could
rescue N-terminal trimethylation levels, though they were
expressed at similar levels for over 72 hours (Fig. 9E).
These data confirm the impaired biochemical activities
of these mutants cannot be overcome in cells with
endogenous substrate levels, even after prolonged exposure.
As loss of NRMT1 function has been shown to alter cellular
growth rates, the ability of N209I and P211S to rescue
cellular proliferation rates in the HCT116 NRMT1 knockout
line was also performed.

As compared to control pSpCas9

transfected cells, the NRMT1 knockout strain grows
significantly slower (Fig. 9F).

This would be expected if

NRMT1 acts as an oncogene in this cell type.

Rescue with

transduction of WT NRMT1 restores proliferation rates (Fig.
9F).

Surprisingly, expression of the N209I mutant also

restores proliferation rates, though the P211S mutation
does not (Fig. 9F).

Why one mutation can restore
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Figure 10. NRMT1 genome editing in HCT116 cells.
(A) NRMT1 target site selected for sgRNA design.
Protospacer adjacent motif (PAM) highlighted in red.
Western blot analysis of first six expanded clones.

(B)
All

clones had reduced NRMT1 (25 kD band) and N-terminal
trimethylation (me3-RCC1) levels as compared to control
(Cont.) cells transfected with empty pSpCas9(BB)-2A-Puro.
*denotes non-specific band recognized by NRMT1 antibody.
(C) DNA frameshift mutation found in clone #6, which was
subsequently used in all experiments.

Cell line was

generated by John Tooley, State University of New York at
Buffalo.
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proliferation and the other cannot, though neither restores
N-terminal trimethylation levels, now remains to be
determined.

These data indicate the NRMT1 mutations are

loss-of-function mutations and not neomorphic gain-offunction alleles, like the EZH2 mutations, and will need to
become homozygous or combined with other NRMT1 loss-offunction mutations before effects on proliferation and
other oncogenic phenotypes will be seen.
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DISCUSSION

My work contributed to the findings that describe a
biochemical alteration in NRMT1 and NRMT2 methyltransferase
activities resulting from mutations identified in human
cancer samples.

In addition, I also showed that NRMT1

mutations in the conserved aromatic residues of the active
site did not result in switched catalytic specificities or
altered levels of substrate methylation.
This is contrary to what is seen in the SET domain
histone methyltransferase EZH2, where mutation of its Y641
residue to either a phenylalanine or asparagine changes its
catalytic specificity from a monomethylase to a
trimethylase (105).
for this divergence.

There are a few possible explanations
First, while EZH2 is a SET domain

methyltransferase, NRMT1 and NRMT2 are seven-b-strand
methyltransferases (46).

Though both types of

methyltransferases contain a series of aromatic residues in
their active site that are reminiscent of the aromatic
cages found in methyllysine-binding proteins and likely
contribute to substrate specificity, they are structurally
distinct methyltransferases which may have different modes
of substrate recognition (46,105).
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Alternatively, in addition to the aromatic residue
composition, there is a second structural feature of NRMT1
and NRMT2 that could dictate catalytic specificity.
Despite the high sequence conservation between NRMT1 and
NRMT2, NRMT2 possesses an extra 60 amino acid N-terminal
domain “tail” which is not found in NRMT1 (46).

Given the

apparent flexibility of this tail, it is possible it could
partially fold over the active site and limit substrate
entrance.

This would then take precedence over the

aromatic residues in substrate selection and binding.
A similar regulatory mechanism is seen in the human
arginine methyltransferase PRMT1 (146).

PRMT1 has seven

alternative splice variants that differ in their N-terminal
composition, and these unique sequences influence both
catalytic activity and substrate specificity (146).

To

address this possibility for NRMT1 and NRMT2, I attempted
to make NRMT2 with the tail domain deleted and NRMT1 with
the tail domain added.

Future experiments will be needed

to fully address this issue.
Although the NRMT1 aromatic cage mutants showed no
alteration in catalytic specificity, the cancer mutations
N209I and P211S (endometrial and lung, respectively) showed
a significant decrease in trimethylase activity and a
significant increase in mono-/dimethylase activity.
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The

NRMT2 breast cancer mutation V224L also showed a
significant decrease in monomethylase activity but lacked a
reciprocal gain in trimethylation activity.

The recently

solved crystal structures of NRMT1 complexed with substrate
peptides illustrates that N209I and P211S are in the
peptide binding channel, (131) and V224 is adjacent to an
asparagine that forms both hydrogen bonds and electrostatic
interactions with substrate, (131) indicating the mutations
do not directly change catalytic specificity but alter
substrate preference.

This is validated by my western

blots showing N209I and P211S are still distributive
enzymes capable of trimethylation.

However, they are less

efficient at methylating unmodified substrate and
converting mono-/dimethylated substrate into trimethylated.
Whether these mutations can act as drivers of
oncogenesis or promote further oncogenic transformation
remains to be elucidated.

My data indicate it may depend

on the type of cancer it is found in.

As seen in the

HCT116 NRMT1 knockout line, cancers that typically
overexpress NRMT1 may find mutants with decreased
trimethylase activity detrimental to their growth.

In

addition, loss of N-terminal trimethylation has been shown
to impair DNA repair, (50,52) so it may also make these
tumors more sensitive to DNA damaging chemotherapeutics or
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g-irradiation.

Cancers, such as breast, that become more

oncogenic with loss of NRMT1 (50) may find these mutations
as helpful drivers of oncogenesis, though the potential for
increased sensitivity to DNA damaging agents would remain.
In the case of NRMT1, I propose its ability to work
both as an oncogene and a tumor suppressor is likely
dependent on which pathways are driving oncogenesis in
specific tissues.

For example, one well-studied NRMT1

target is the tumor suppressor retinoblastoma protein (Rb).
It was previously shown that NRMT1 is acting as a tumor
suppressor in estrogen receptor (ER) positive MCF-7 breast
cancer cells, as its loss promotes DNA damage accumulation,
and increased proliferation, migration, and xenograft tumor
formation (50).

Patients with ER+ tumors have poorer

disease outcomes if they have an Rb mutation (147).

If

methylation of Rb by NRMT1 activates Rb-dependent
transcription, loss of NRMT1 could mimic an Rb mutation and
increase oncogenicity.
In contrast, NRMT1 is found overexpressed in colon
cancers, (143-145) indicating it may be acting as an
oncogene in this tissue.

One difference between breast

cancers and colon cancers is that colon cancer cells
harboring activating K-Ras mutations require wild type Rb
for oncogenic transformation and prevention of apoptosis
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(148,149).

Thus, in this particular tumor type,

overexpression of NRMT1 could be beneficial.
Little is known about NRMT1 expression levels in human
lung cancer samples, though one study found a 1.5-fold
decrease in NRMT1 expression in non-small cell lung
carcinomas (NSCLC) (138).

Unlike small cell lung

carcinomas (SCLC), which frequently harbor Rb mutations,
NSCLC tumors favor mutation in CDKN2A (150).

As an

inhibitor of MDM2 activity, CDKN2A indirectly controls both
p53 and Rb protein levels, so NSCLC cancer harboring both a
CDKN2A and NRMT1 mutation would have reduced levels of Rb
with potentially reduced activity.
In fact, the NRMT1 P211S mutation was found in a cell
line derived from a metastatic lymph node of a patient with
NSCLC (137), and Functional Analysis through Hidden Markov
Models (FATHMM), which predicts the functional consequences
of single nucleotide variants, rates it as strongly
pathogenic (Cosmic Catalogue of Somatic Mutations in
Cancer).

The NRMT1 N209I mutation was identified as a

somatic mutation in an endometrial tumor sample and also
has a strongly pathogenic FATHMM prediction (Cosmic
Catalogue of Somatic Mutations in Cancer).

Of the 48

currently reported NRMT1 cancer mutations, eight are
missense mutations in the L4 and L67 loop regions that help
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create the peptide-binding channel, and seven of these
eight mutations have strongly pathogenic FATHMM predictions
(Cosmic Catalogue of Somatic Mutations in Cancer).
My supposition that NRMT1 can act as an oncogene or a
tumor suppressor, dependent on the type of cancer, is based
on the under- or overexpression of NRMT1 seen in different
cancer types.

This dual type of behavior is not uncommon.

There are proteins which have been documented to act as an
oncogene or a tumor suppressor in different cancers, or
even in the same cancer type.

E-cadherin is commonly

considered a tumor suppressor, and its loss occurs in many
epithelial cancers, including colon and liver cancers
(151,152).

On the other hand, the overexpression of E-

cadherin has also been observed in advanced glioblastoma
tumors, and its knockdown in SF767 glioma cells inhibited
proliferation (153).
Another example is RAD9, which participates in DNA
repair and cell cycle regulation.

It can act as an

oncogene in breast cancer, and its overexpression has also
been correlated with prostate and thyroid cancers.

It has

been additionally reported that deletion of RAD9 in mouse
keratinocytes leads to the development of skin cancer,
suggesting its role as a tumor suppressor in such a context
(154).

Lastly, RASSF1 seems to function as a tumor
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suppressor in most neuroendocrine lung tumors, but as an
oncogene in neuroendocrine lung tumors that are high grade
(155).
Why loss of N-terminal trimethylation by NRMT1 would
result in phenotypes despite the continued presence of
monomethylation by NRMT2 (or NRMT1 mutants) also remains to
be elucidated.

As with lysine methylation, I predict the

different levels of N-terminal methylation promote
different functional outcomes.

For example, in the case of

histone H4 lysine 20 (H4K20) methylation, monomethylation
promotes transcriptional elongation by recruiting the MSL
complex, increasing local histone H4 lysine 16 acetylation,
and releasing RNA polymerase II (Pol II) into active
elongation (22).

In contrast, H4K20 trimethylation

promotes Pol II pausing by inhibiting MSL recruitment (22).
These distinct functional outcomes are driven by the
specificity of the MSL chromodomain for H4K20 mono- and
dimethylation and its inability to bind trimethylation
(77).

Whether the different levels of N-terminal

methylation also have readers with distinct structural
domains or whether monomethylation simply is unable to
promote strong DNA-protein interactions are currently under
investigation.
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The discovery of the Y641 EZH2 mutations as drivers of
B cell lymphoma has led to the development of many new EZH2
inhibitors.

Two of these inhibitors, GSK126 and EPZ-6438,

both highly selective S-adenosyl-methionine-competitive
small molecule inhibitors, have been respectively shown to
inhibit the proliferation of EZH2 diffuse large B-cell
lymphoma cell lines and mouse xenografts expressing the
Y641 mutation (156-158).

However, unlike the EZH2 Y641

mutations, the identified NRMT1 mutations are not gain-offunction, and therapeutic use of NRMT1 inhibitors would
have to be context specific.
In tumors such as colorectal, that significantly
overexpress NRMT1, NRMT1 inhibitors could be a viable
therapeutic option (143-145).

In breast cancers, however,

use of NRMT1 inhibitors alone could be detrimental, but
beneficial in combination with DNA-damaging
chemotherapeutics or g-irradiation.

As it has been shown

that neither the N209I or P211S NRMT1 mutations can restore
N-terminal trimethylation after loss of NRMT1, homozygosity
for these mutations may also be a useful marker for tumors
especially susceptible to chemo and irradiation therapies.
Novel bisubstrate analogues and potent inhibitors of NRMT1
have recently been designed and continue to be optimized,
(159,160) and it will be interesting to see if any of the
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derivatives affect cancer cell proliferation and/or
sensitivity to chemo and radiation therapy in a tissuespecific manner.
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CHAPTER III: ASSESSING THE CELLULAR EFFECT OF NRMT1 MUTANTS
DURING THE DNA DAMAGE RESPONSE

BACKGROUND

From the data in Chapter II, I demonstrated that the
NRMT1 cancer mutants (N209I, endometrial cancer; P211S,
lung cancer) impair catalytic activity in vitro (Figs. 2,
5-7) (109).

However, the significance of this in a

cellular context is unclear and is the focus of the work
presented in this chapter.
In the MCF-7 and LCC9 breast cancer cell lines, the
loss of NRMT1 resulted in an increased sensitivity to DNA
damage (50,51).

Additionally, NRMT1 knockout MEFs display

an increased sensitivity to oxidative damage (51).
Together, these data suggest that NRMT1 may be crucial for
cell survival in response to cellular insults.

Given that

the N209I and P211S mutants are also incapable of rescuing
N-terminal trimethylation activity in cells (Fig. 9) (109),
I hypothesize that they will be unable to promote cell
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survival of NRMT1 knockout cells in response to DNA
damaging agents.
DNA damaging agents are often employed as
chemotherapeutic agents in the treatment of cancer.

Two

examples include etoposide (brand name Etopohos) and
doxorubicin (brand name Adriamycin).

Etoposide

intercalates with DNA, causing DNA DSBs, and is also a
topoisomerase II inhibitor.

It is capable of inducing

caspase-mediated apoptosis at high concentrations (161163).

Doxorubicin belongs to the anthracycline class of

drugs (161), and it also intercalates with DNA, causing DNA
DSBs.

Additionally, it can also cause oxidative stress

(161,164-166), leading to the mitochondrial route of
apoptosis (167-169).

While NRMT1-depleted cells have a

heightened sensitivity to etoposide (50), their response to
doxorubicin remains untested.
To begin to address this question, I utilized NRMT1deficient HCT116 cells that had already been generated
using CRISPR technology (Fig. 10; hereby referred to as KO
cells).

An additional advantage of using these cells is

based on their similarity to MCF-7 cells, in regards to
having wild-type p53 status (170).

Thus, to investigate

whether the N209I or P211S mutations in NRMT1 would have
any functional consequence in the context of cellular
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proliferation or DNA damage, I expressed these mutants, as
well as wild-type NRMT1, into the KO cell line, and
assessed their sensitivity towards doxorubicin.
The cellular response towards DNA damaging agents
(specifically, doxorubicin) has been extensively
characterized (171).

In the absence of p53, or its

downstream target p21, cells exhibit an increase in
doxorubicin-induced cell death (172).

Thus, as an

additional measure, I monitored p53 and p21 expression in
my cell lines.
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MATERIALS AND METHODS

Constructs and Antibodies

To generate C-terminal GFP-tagged NRMT1 constructs,
human NRMT1 (GE Dharmacon, Marlborough, MA), which had been
subcloned into the pKGFP2 vector, was used as the template
for site-directed mutagenesis to produce N209I and P211S
NRMT1 using the Quikchange site-directed mutagenesis
protocol (Agilent Technologies, Santa Clara, CA).

The

following forward primers and their reverse complements
were used:
N209I: 5’-GAGGAGAGGCAGGAGATCCTCCCCGATGAGATC-3’
P211S: 5’-GGCAGGAGAACCTCTCCGATGAGATCTACC-3’
Both mutants were confirmed by DNA sequencing.
Primary antibodies used for western blots are as
follows: 1:5000 polyclonal rabbit anti-me1/2RCC1 (mono/dimethylated SPK-RCC1) (120), 1:10,000 polyclonal rabbit
anti-me3RCC1 (trimethylated SPK-RCC1) (120), 1:1000
polyclonal goat anti-RCC1 (Santa Cruz Biotechnology, sc1162, Santa Cruz, CA), 1:2000 polyclonal rabbit anti-NRMT1
(128), 1:500 monoclonal rabbit g-H2AX (Abcam, 20E3,
Cambridge, United Kingdom), 1:1000 monoclonal rabbit HSP90
(Cell Signaling Technology, C45G5, Danvers, MA), 1:1000
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monoclonal mouse a-tubulin (Sigma Aldrich, St. Louis, MO),
1:1000 monoclonal mouse p53 (Santa Cruz Biotechnology, sc098), 1:1000 polyclonal rabbit p21 (Santa Cruz
Biotechnology, sc-397), 1:1000 monoclonal mouse Rb, and
1:1000 monoclonal mouse DDB2 (Abcam, ab51017).

1:1000

polyclonal rabbit anti-Mettl11a/NRMT1 (Abcam, ab102664) was
used to detect KO+WT, and KO+N209I and KO+P211S NRMT1.
Secondary antibodies used were as follows: goat anti-rabbit
IRDyeÒ 680 RD (Li-Cor, 926-68071, Lincoln, NE), goat antimouse IRDyeÒ 800 CW (Li-Cor, 926-32210), and donkey antigoat IRDyeÒ 800 CW (Li-Cor, 925-32214).

All antibodies were

diluted in 2% BSA (in TBST).
SDS polyacrylamide gel electrophoresis (SDS PAGE) was
performed using tris-glycine separation with running buffer
(25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3).

Gels were

run at 125V until the bromophenol blue tracker dye reached
the end of the gel (approximately 90 minutes).

Proteins

were transferred to nitrocellulose membranes for 90 minutes
at a constant current of 400mA in transfer buffer (25 mM
Tris, 192 mM glycine, pH 8.3), which were then blocked
using 2% BSA in TBST for one hour at room temperature.
After the blocking step, incubation with the primary
antibodies was performed at 4 °C overnight (18-20 hours) on
an end-over-end rocker.

Washing was performed using TBST.
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Incubation with secondary antibodies was performed for one
hour at room temperature.

After the final washing steps,

the membranes were imaged using the LI-COR Odyssey Blot
imager.

Cell Culture

HCT116 human colorectal carcinoma cells lines (a
generous gift from Dr. Ian Macara, Vanderbilt University)
were maintained in Dulbecco’s Modified Eagle Medium (DMEM)
(Corning Life Sciences, Manassas, VA) with 10% fetal bovine
serum (FBS) (VWR, Radnor, PA) and 1% penicillinstreptomycin-glutamine (P/S/G) (Life Technologies) and were
used at a passage number of less than 25.

To generate

KO+WT (WT), KO+N209I (N209I), and KO+P211S (P211S) cells
(referred to collectively as rescue cells), NRMT1 KO cells
were transduced with WT NRMT1, N209I, and P211S lentivirus
(production detailed in Chapter II Materials and Methods)
to a MOI of 1.

Calculations performed to estimate MOI are

based on the detection of GFP-positive cells by microscopy,
and the dilution of virus necessary to achieve this.
Virus-containing media was replaced with virus-free media
three days later.
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Cell Growth Assays and Drug Treatment

Seeding conditions were 5.0 X 104 cells per well in 12well plates (only fig. 14 HCT116 toleration of doxorubicin
treatment), 2.4 X 104 cells per well in 24-well plates, or
1000 cells per well in 96-well plates; figure legends
indicate which condition was used.

For viability (cell

growth) assays (CellTiter 96â AQueous One Solution Cell
Proliferation Assay), cells were plated in triplicate in
24-well (or 96-well) plates in 500 µL (or 100 µl) of media.
For experiments examining DNA damage, cells were treated
with doxorubicin (dox) (Sigma Aldrich) at 0, 0.1, or 1 µM 24
hours following seeding.

After the treatment time or day

of measured growth (indicated by figure legend), or
recovery time post-treatment (48 hours), 80 µl (for 24-well
plates) or 20 µl (for 96-well plates) of Aqueous One
Solution (Promega, Madison, WI) was added to all
replicates, and the absorbance at 490 nm was read after two
hours.

Data was analyzed by two-way ANOVA and Tukey’s

post-hoc test.
For western blots, cells were seeded according to
either seeding condition outlined above; figure legends
indicate which condition was used.
treated as indicated above.

Cells were plated and

Following the indicated
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treatment (24 hours) or recovery time post-treatment (48
hours), cells were lysed in 2X Laemmli’s SDS-Sample Buffer
(4X, Boston Bioproducts, Ashland, MA) supplemented with bmercaptoethanol (5% v/v).

Immunofluorescence Experiments

To assess the subcellular localization of the mutants,
3.0x105 HCT116 cont. cells were seeded on coverslips in 6well plates.

The jetPRIMEÒ transfection reagent (Polyplus,

New York, NY) was used to transiently transfect 0.5 µg WT
NRMT1, N209I, or P211S, which were all C-terminally GFPtagged.

For each transfection, 2 µl of jetPRIME reagent was

added to the DNA in 200 µl of the provided buffer.

After an

incubation of 25 minutes, the transfection mixture was
added directly to the cells.

18 hours post-transfection,

media was removed, cells were washed with PBS and then
fixed in 10% formalin for 10 minutes at room temperature.
Coverslips were mounted with Vectashield containing DAPI
(Vector Laboratories, Burlingame, CA).

Cells were imaged

using a confocal fluorescence microscope (Olympus IX SLA).
Images were then imported into Photoshop (Adobe Systems,
Inc.) for processing.

Images are from one section and are

not an overlay.
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For studies with doxorubicin and g-H2AX foci
visualization, 5.0x105 HCT116 cont. and NRMT1 KO cells were
seeded on coverslips in 6-well plates.

One day after

seeding, media was removed, and cells were treated with 0,
0.1, or 1 µM doxorubicin for 24 hours.

Cells were fixed in

10% formalin as above, followed by permeabilization in 0.5%
Triton X-100 in PBS for 5 minutes at room temperature.
Cells were then blocked for one hour in 2% BSA/1% goat
serum in PBS.

Stain and antibodies used are as follows:

primary 1:500 rabbit g-H2AX (Abcam, 20E3), prepared in 2%
BSA/1% goat serum in PBS; 1:250 rhodamine phalloidin
(Molecular Probes, R415, Eugene, OR), prepared in 2% BSA/1%
goat serum in PBS; and secondary 1:1000 goat a-rabbit Alexa
FluorÒ 488 (Invitrogen, A11008, Carlsbad, CA), prepared in
2% BSA/1% goat serum in PBS.

Primary antibody incubation

was one hour at room temperature; rhodamine phalloidin and
secondary antibody incubation was for 30 minutes at room
temperature in the dark.

Coverslips were mounted with

Vectashield containing DAPI (Vector Laboratories).

g-H2AX,

phalloidin, and DAPI were visualized by confocal microscopy
as described above.
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siRNA Knockdown Experiments

To assess the effects of transient knockdown of NRMT1
in HCT116 cells, cells were seeded at a density of 2.4 X 104
cells per well in a 24-well plate.

Two days after seeding

(when cells had reached approximately 70% confluency),
transfection was performed using 10 pM siRNA.

The target

sequences for the siRNA oligos utilized are as follows:
NRMT1 a, 3’UTR: CTGGCAGGAGAAACTGAGGAA
NRMT1 b, 3’ UTR: GAGTGTCGAGGCACCACTAAA
NRMT1, ORF: GGCCCGAACAAGACAGGAAtt (sense);
UUCCUGUCUUGUUCGGGCCtt (antisense)
21 hours post-transfection, media was replaced, and cells
were treated with 1 µM doxorubicin or 250 µM etoposide for
six hours.

Cell lysates were then analyzed for NRMT1

knockdown by western blot analysis.
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RESULTS

Mutant NRMT1 Methylation Pattern Is Not Unique to RCC1

From Chapter II, the methylation pattern for RCC1
displayed by the NRMT1 cancer mutants was established using

in vitro methyltransferase assays.

To determine the

pattern in a cellular context, I independently reestablished these cell lines by stably expressing these
mutants in HCT116 cells lacking endogenous NRMT1.
Specifically, I used lentivirus expressing WT, N209I, and
P211S NRMT1.

The cells were established, and the

expression was confirmed by western blot (Fig. 11).

As a

CRISPR control, I used cells expressing pSpCas9 only
(hereby referred to as cont. cells).
Western blots with the trimethylated SPK (me3RCC1)
antibody shows that only WT NRMT1 was able to rescue the
trimethylation pattern (Figs. 9, 11, 23).

Thus, while the

in vitro data suggested that the NRMT1 cancer mutants
possessed an inefficient ability to trimethylate
substrates, they could not do so in a cellular context.
NRMT1 recognizes over 300 putative targets (44) with
many different consensus sequences; however, only a handful
of those substrates possess the SPK consensus sequence.
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Figure 11. NRMT1 KO cells transduced with lentivirus.
NRMT1 KO cells were transduced with lentivirus expressing
WT, N209I or P211S NRMT1 at a MOI of 1.

After cells were

established, protein lysates were obtained, and western
blot performed with the indicated antibodies.

NRMT1

expression and trimethylation of RCC1 in WT lane is
comparable to that of cont., while this is barely
detectable in the N209I and P211S lanes.

Mono-

/dimethylation of RCC1 is the same across all five cell
lines.

The levels of RCC1 are also the same in all lines.

HSP90 was used as a loading control.

Shown is a

representative Western blot from three independent
experiments.
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From Figure 23, the band that migrates at 45 kD (indicated
by the asterisk) is RCC1.
The other prominent band detected by the tri-SPK
antibody migrates at approximately 20 kD.

According to

Petkowski et al. (44) (who expanded the originally defined
NRMT1 consensus sequence, as well as performed additional
in-depth work to pinpoint putative NRMT1 targets), a
protein of this size possessing the SPK sequence could
potentially be the VCX-A protein.

However, VCX-A has only

been detected in the testis and germ cells, linking it with
potential roles in spermatogenesis (173).

Thus, the exact

identity of this band in HCT116 cells has yet to be
elucidated.

Nevertheless, the presence of this band was

also rescued by wild-type NRMT1 in the KO cells.

N209I Subcellular Localization Differs from WT NRMT1

The subcellular localization of WT NRMT1 is
predominantly nuclear (46,47).

To determine if the NRMT1

mutants localize appropriately, I performed confocal
microscopy.

HCT116 cont. cells were transfected with C-

terminally GFP-tagged WT, N209I, or P211S constructs, and
processed for confocal microscopy.
visualized by DAPI staining.

The nucleus was

From two independent
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experiments, WT NRMT1 displayed the predominantly nuclear
localization pattern, with minimal cytoplasmic
localization, as expected (Fig. 12).

Similarly, the

subcellular localization of the P211S mutant was also
predominantly nuclear (Fig. 12).

In contrast, the N209I

mutant exhibited noticeably more cytoplasmic localization
(Fig. 12).

Thus, in addition to loss of trimethylation

activity, the N209I mutant may exhibit reduced nuclear
localization in cells.

Viability Studies of HCT116 Cells

Prior to studying DNA damage in the HCT116 cells, I
examined the proliferation levels of the cell lines that I
re-established, to determine if the cancer mutants could
rescue the proliferation defect in KO cells that was
previously described (109).

Using the CellTiter assay, I

assessed the proliferation of the five cell lines on days
0, 1, 3, and 5 after seeding.

A total of nine experiments

were performed on separate days with a summary graph shown
in Figure 13 (Fig. 24 in the Appendix).
The summary graph shown in Figure 13 exemplifies the
type of data recorded.

In eight out of the nine

experiments, the KO cells proliferated more slowly than the
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Figure 12. Subcellular localization of WT and mutant NRMT1.
(A-B) HCT116 cells were transiently transfected with Cterminally GFP-tagged WT, N209I or P211S NRMT1.

After 24

hours, cells were processed for confocal microscopy using
the Olympus IX SLA microscope.
are shown.

DAPI, GFP, and merge images

Images were obtained using a 40X objective with

3.0X digital magnification.

Bar, 20 µm.

one section and are not an overlay.

Images are from

WT and P211S NRMT1

show predominantly nuclear localization.

N209I manifests

greater cytoplasmic localization, compared to WT.
Experiment was performed twice.
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Figure 13. Viability studies of HCT116 cells.
Four sets of triplicates were made for each of the five
HCT116 cell lines.

Cells were seeded at a density of 1000

cells per well in 96-well plates on day 0.

On the day of

plating (day 0), 20 µl of Aqueous One Solution (Promega,
Madison, WI) was added to the first set of triplicates for
each cell line, and the absorbance at 490 nm was read after
two hours.

Readings were also taken on days 1, 3, and 5.

Raw absorbance values are shown on the Y-axis.

Results

shown are the mean ± standard deviation of data from nine
independent experiments and triplicate measurements per
experiment.

Individual experimental results are shown in

Figure 24.
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cont. cells (Figs. 13, 24), in agreement with what I
previously reported (109).

This is especially apparent on

Day 5 of the assay (Figs. 13, 24).

However, in my

experiments, the expression of WT protein into the KO cells
did not rescue the proliferation defect as was previously
shown (109).

DNA Damage Studies of HCT116 Cells Towards Doxorubicin

I next assessed whether my cell lines would exhibit
differences in response to DNA damage, given that previous
work demonstrated that NRMT1-depleted cells have a
heightened sensitivity to DNA damaging agents (50,51).

For

example, NRMT1 knockdown breast cancer cells treated with
the DNA-damaging agent etoposide had slower rates of
proliferation, as well as an increase in g-H2AX foci, which
is an early indicator of DNA damage (50,174,175).

I

decided to use doxorubicin as the DNA damaging agent, given
that the effect of this drug has been well characterized
(171).
Typically, a dose of 0.1-1.0 µM doxorubicin causes cell
death in HCT116 cells after 24 hours (172).

Prior to

determining the effects of doxorubicin on DNA damage
signaling, cells were first treated to confirm that
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doxorubicin caused cell death in my HCT116 cell lines.
HCT116 cont. and NRMT1 KO cells were treated with 0.1 or 1
µM doxorubicin for 24 hours or left untreated as a control
(Fig. 14).

Cells were then allowed to recover for 48 hours

following doxorubicin treatment.

The micrographs from two

independent experiments are shown in Figure 14.

As

expected, doxorubicin caused cell death at both
concentrations, but especially at 1 µM (Fig. 14).
To quantitatively measure the cell viability in
response to doxorubicin, I performed CellTiter assays (the
reduction of a metabolite is correlated to the number of
viable cells).

I first assessed this in the cont. and KO

cells after treating with doxorubicin for 24 hours.

A

total of five experiments were performed with a summary
graph depicted in Figure 15 (Fig. 25 in the appendix).
There was a trend for KO cells to exhibit increased
sensitivity toward doxorubicin at 1 µM.
I then performed four additional series of experiments
to include the rescue cell lines.

This time, I only

treated the cells at 1 µM doxorubicin for 24 hours, along
with untreated controls.
16 and 26.

The data are depicted in Figures

In this set of experiments, the KO cells were

not consistently more sensitive to the doxorubicin
treatment, indicating this trend was not
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Figure 14. HCT116 toleration of doxorubicin treatment.
(A-B) 5.0 X 104 cells per well were seeded into 12-well
plates.

HCT116 cont. and NRMT1 KO cells were treated with

0, 0.1, or 1 µM doxorubicin for 24 hours.

Afterward, media

was replaced, and cells were allowed to recover for 48
hours.

Representative pictures were taken immediately

following recovery period.

Experiment was performed twice;

total magnification was 10X.
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Figure 15. Viability assay of doxorubicin-treated cont. and
NRMT1 KO cells.
2.4 X 104 cells per well were seeded into 24-well plates.
Three sets of triplicates were made for cont. and NRMT1 KO
cells.

CellTiter was performed on cells that were treated

with 0.1 or 1 µM doxorubicin (or the untreated controls) for
24 hours.

Following treatment, 80 µl of Aqueous One

Solution was added to each well, and the absorbance at 490
nm was read after two hours.

Y-axis units are arbitrary

units of absorbance at 490 nm.

Results shown are the mean ±

standard deviation of data from five independent
experiments and triplicate measurements per experiment.
Individual experimental results are shown in Figure 25.

116

Absorbance 490nm

1.0

Cont.
NRMT1 KO

0.8

WT

0.6

N209I

0.4

P211S

0.2
0.0

UNT

1 µM

Dox Concentration

117

Figure 16. Viability assay of doxorubicin-treated cells.
2.4 X 104 cells per well were seeded into 24-well plates.
Two sets of triplicates were made for each cell line.
CellTiter was performed on cells that were treated with 1 µM
doxorubicin (or the untreated controls) for 24 hours.
Following treatment, 80 µl of Aqueous One Solution was added
to each well, and the absorbance at 490 nm was read after
two hours.

Y-axis units are arbitrary units of absorbance

at 490 nm.

Results shown are the mean ± standard deviation

of data from four independent experiments and triplicate
measurements per experiment.

Individual experimental

results are shown in Figure 26.
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reproducible.

Also, similar to Figure 13, WT cells did not

rescue proliferation levels, and neither mutant cell line
grew significantly differently than the KO cells.
Since my data thus far suggested that NRMT1 did not
have an effect on cell viability after 24-hour treatment, I
performed another set of experiments to assess whether
NRMT1 might have a role at later time points (i.e. during
the recovery phase).

Thus, I performed two additional

series of experiments using 1 µM doxorubicin and assessed
cell viability after 48 hours.

As can be seen from the

data (Fig. 17), there was no consistent difference between
the cell lines after treatment.

Assessment of g-H2AX Foci After Treatment with Doxorubicin

My data, thus far, is different than what was reported
for the role of NRMT1 in etoposide-treated or irradiated
breast cancer cells (50).

I therefore wanted to ensure

that, in my experiments, I was indeed inducing DNA damage.
When cells are exposed to ionizing radiation or other
DNA damaging agents, the histone H2A variant, H2AX, becomes
phosphorylated at sites of DSBs on residue Ser 139
(referred to as g-H2AX) (174,175).

This is an early event

in the DNA damage response (174,175), and is thus a
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Figure 17. Viability assay of recovered doxorubicin-treated
cells.
2.4 X 104 cells per well were seeded into 24-well plates.
Two sets of triplicates were made for each cell line.
CellTiter was performed on cells that were treated with 1 µM
doxorubicin (or the untreated controls) for 24 hours
followed by a 48-hour recovery period.

After treatment and

recovery, 80 µl of Aqueous One Solution was added to each
well, and the absorbance at 490 nm was read after two
hours.
490 nm.

Y-axis units are arbitrary units of absorbance at
Results shown are the mean ± standard deviation of

data from two independent experiments and triplicate
measurements per experiment.
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suitable marker for this process.

Therefore, as a first

step to assess the DNA damage in the treated cells,
confocal microscopy was performed.

In brief, treated cells

were fixed and probed with an antibody against g-H2AX, which
has an epitope against the phosphorylated residue Ser 139.
In the absence of doxorubicin, g-H2AX foci could not be
observed in untreated cells, as expected (Fig. 18).
However, after 24-hour doxorubicin treatment, g-H2AX was
readily detected.

To confirm this, I also performed

western blot analysis using the same antibody.

In

agreement with the confocal results, the western blots
showed an increase in g-H2AX signal after doxorubicin
treatment, suggesting that indeed, doxorubicin was causing
DNA damage. Additionally, the similar levels of g-H2AX in
all the cell lines is consistent with the proliferation
results.

Western Blot Analysis of Doxorubicin Treatment

While previous data has shown that loss of NRMT1 leads
to an increased sensitivity to etoposide in breast cancer
cell lines, my data shows that NRMT1 has no effect in
doxorubicin-treated HCT116 cells.

One explanation for

these differences could be attributed to the different
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Figure 18. g-H2AX foci following 24-hour doxorubicin
treatment.
(A) Cells were seeded at a density of 5.0x105 cells onto
coverslips in 6-well plates.

Cells were then treated with

1 µM doxorubicin for 24 hours before processing for confocal
microscopy using the Olympus IX SLA microscope to visualize
DAPI, g-H2AX (p-H2AX), and phalloidin (actin).
and merge images are shown.

DAPI, GFP,

Images were obtained using a

40X objective with 3.0X digital magnification.

Bar, 20 µm.

Images are from one section and are not an overlay.

Merge

of each CTL (cont.) and KO condition shown on far right.
Top two rows show untreated cells (Unt), and bottom two
rows show cells treated with 1 µM doxorubicin for 24 hours.
Bar, 20 µm.

(B) For western blots, cells were seeded at a

density of 2.4 X 104 cells per well in 24-well plates.
Western blots show doxorubicin-treated cell lysates that
were probed for HSP90, as a loading control, and g-H2AX.
This experiment was done once.
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treatments and cell lines employed.

However, it is also

possible that compensatory changes in signaling pathways
might be a factor.

As such, I decided to perform western

blots to look into a few key proteins involved in the DNA
damage response.
For the first experiment, cont. and KO cells were
treated with 1 µM doxorubicin for 24 hours, followed by
recovery for 48 hours.
control.

Untreated cells were used as a

Lysates were obtained, and western blots were

performed with the indicated antibodies (Figs. 19 and 21).
Tubulin was used as a loading control, and the absence of
NRMT1 and the me3RCC1 signal confirmed the identity of the
KO cells.

Next, I assessed the p53 and p21 levels, given

their importance in the DNA damage response in HCT116
cells.

After treatment with 1 µM doxorubicin for 24 hours,

both p53 and p21 exhibited increased levels in both cell
lines.

After an additional 48 hours (during recovery), p53

and p21 expression were still elevated in cont. cells, when
compared to untreated cells.

However, in the KO cells, the

levels of these two proteins had returned to levels
comparable to untreated cells.
Although this observation in the differences in p53
and p21 levels seemed promising, subsequent experiments
indicated that it was not reproducible.
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For the next
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Figure 19. DNA damage signaling of cont. and NRMT1 KO
cells.
5.0 X 104 cells per well were seeded into 12-well plates.
Cells were then treated with doxorubicin at the indicated
concentrations for 24 hours, and then immediately lysed
(A), or the media was replaced, and cells were allowed to
recover for 48 hours before lysis (B).

Western blot

analysis was conducted using the antibodies indicated in
the figure.

Blots are representative images of three

independent experiments.
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series of experiments, I performed western blot analysis as
indicated above for all five lines.

For example, in one

set of data, after treatment with doxorubicin for 24 hours,
p53 expression was elevated (Figs. 20A and 21).

However,

p21 expression was barely detectable.
In another set of experiments, I performed western
blot analysis during the recovery period (Figs. 20B and
21).

In this instance, p53 expression was elevated when

compared to untreated cells; however, the levels of p53
were the same in each line.

Thus, the difference in p53

levels observed in Figure 19 was not reproducible.
Finally, I also evaluated a couple of NRMT1 substrates
to see if they exhibited expression differences.
Specifically, I looked at Rb and DDB2, which are known to
be involved in the DNA damage response (50).

As shown in

Figure 20B, there was no appreciable difference in the
expression of these two proteins among the five cell lines.
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Figure 20. DNA damage signaling of rescue cell lines.
The five HCT116 cell lines were seeded at 2.4 X 104 cells
per well in 24-well plates.

Cells were then treated with 0

or 1 µM doxorubicin for 24 hours, and then immediately lysed
(A), or the media was replaced, and cells were allowed to
recover for 48 hours before lysis (B).

Western blot

analysis was conducted using the antibodies indicated in
the figure.

Results are representative of two independent

experiments.
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Figure 21. DNA damage signaling quantification.
Densitometry quantification of p53 (A) and p21 (B) bands
for the 1 µM doxorubicin treatment.

The quantification

pertains to western blots displayed in figures 19 and 20.
For comparison purposes, cont. 24h treatment was set to
1.0.

Quantification for p53 was performed from three

independent experiments, while quantification for p21 was
performed from two independent experiments (blank p21 blots
in Figure 20 not included).
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DISCUSSION

Recent work has experimentally verified a handful of
predicted NRMT1 substrates and has determined that the Nterminal trimethylation by NRMT1 is necessary for their
function (20,52,118,119).

Studies have furthermore

detailed the peptide-binding channel of NRMT1 (110), as
well as resolved the enzymatic mechanism of NRMT1 (133).
Despite this crucial work to uncover basic knowledge about
NRMT1, little attention has been devoted to the impact of
NRMT1 cancer mutants on basic cellular function and the
response to DNA damage.

Importantly, therefore, my work

was the first attempt to address the role of the NRMT1
cancer mutants N209I (endometrial) and P211S (lung) in the
DNA damage response.
I first examined the mutant NRMT1 methylation pattern
in cells.

Despite my in vitro data showing that the N209I

and P211S mutants are catalytically inefficient and slower
enzymes (Chapter II), they both lacked the ability to
rescue trimethylation in HCT116 cells.

The reason for the

difference between the in vitro and cellular data is
unknown but could potentially be due to regulation.

In an

in vitro methylation reaction, the only factors present are
enzyme, substrate, and SAM methyl donor.
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In a cellular

environment, however, there are also, likely, factors
present that contribute to the regulation of methylation
reactions. Future studies to identify these factors should
provide important insight into NRMT1 function.
I furthermore found that the N209I mutant exhibited a
more pronounced cytoplasmic localization when compared to
WT protein.

Although the significance of this is not

known, one could easily speculate that this would affect
the access of NRMT1 to its substrates or binding partners.
Next, I examined the effect of the cancer mutants on
cellular proliferation.

We previously reported that loss

of NRMT1 in HCT116 cells causes decreased proliferation
(109), an observation that I reproduced.

However, in these

later studies, expression of WT NRMT1 failed to rescue the
proliferation defect.

Similarly, expression of the cancer

mutants also had no effect when compared to KO cells.

The

data are not in agreement with what I have reported (109),
which showed that both WT and N209I could rescue the
proliferation defect of KO cells.
I offer the following possibility for the above
discrepancy.

RCC1 was one of the first NRMT1 substrates

identified and characterized (47).

Experiments in MDCK

cells showed that a methylation-defective mutant of RCC1
bound to chromatin less than wild-type protein during
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mitosis and caused spindle-pole defects (120,122).

Thus,

the loss of NRMT1 (and defective RCC1 methylation) could
result in adaptive changes in cells to bypass this crisis.
This could be one plausible explanation as to why reexpressing wild-type NRMT1 had no effect in KO cells that
had been established.

An alternative approach to

circumvent this problem was to introduce transient NRMT1
deficiency by siRNA knockdown.

Unfortunately, after trying

three different siRNA oligos, I could not achieve
successful knockdown in HCT116 cells (Fig. 27).
This was not a technical issue, as a control siRNA
targeting an unrelated gene worked well (Fig. 27).
Nevertheless, I evaluated whether expression of the NRMT1
cancer mutants or WT protein would have any effect during
the DNA damage response.

Although initial experiments

suggested that KO cells were more sensitive to doxorubicin,
those results were not reproducible.

Furthermore, the

response of the rescue cell lines towards doxorubicin was
not significantly different compared to that of KO cells.
As such, I conclude that NRMT1 likely has no effect on the
DNA damage response in HCT116 cells in response to
doxorubicin.
If adaptive changes have occurred in the KO cells, as
I mentioned above, then obviously this could also be a
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contributing factor to how the cells respond to
doxorubicin.

Besides the possibility of adaptive changes,

there are some other possible technical explanations for
the discrepancy observed.
First, cells could be positive for mycoplasma and
affected by it.

Second, my cell lines had not been

authenticated since the time that they were originally
obtained from ATCC.

As these HCT116 cells were obtained

several years ago, it is possible that cross-contamination
or even mis-labelling had occurred.

Third, high passage

numbers of the cells could result in genetic drift and
alter cell characteristics and phenotypes over time.
Additionally, the ATCC media recommendation for HCT116
cells is McCoy’s 5A.

Despite this recommendation, I used

DMEM media (as other studies have also done for HCT116
cells (176,177)), which could potentially contribute to
changes in growth or other characteristics over time.
Lastly, an equally plausible scenario is that NRMT1
could be crucial for the DNA damage response in breast
cancer cell lines, but not in HCT116 cells.

In breast

cancer cell lines, it has been shown that the depletion of
NRMT1 and treatment with etoposide decreased cell
viability.

The treatment also produced more g-H2AX foci in

the NRMT1-depleted cells (50).

136

In my experiments with doxorubicin in HCT116 cells, 1
µM treatment did not result in enhanced DNA damage
sensitivity, unlike in the original experiments with breast
cancer cell lines employing etoposide treatment (50).
Thus, if the effect of the NRMT1 cancer mutants are to be
further studied in the context of DNA damage, it would seem
more sensible to do so in breast cancer cell lines.
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CHAPTER IV: FUTURE DIRECTIONS

My dissertation research was born out of an interest
sparked from a 2011 study.

That work demonstrated that

some B-cell lymphoma patients possess a Y641 aromatic cage
active site mutation in the histone methyltransferase EZH2
(105,111,115).

The mutation was found to change the

catalytic specificity of EZH2 from a mono- to a
trimethylase (105,111,115).

This altered gene expression

and increased oncogenicity (105,111,115).

These findings,

coupled with a similarity in the spatial alignment between
EZH2 and NRMT1/2, lead me to pursue whether the catalytic
specificities of NRMT1 or NRMT2 are altered by their
harbored mutations found in some cancers, or in the
aromatic cage itself.
My findings from Chapter II show that the aromatic
cage mutations of both NRMT1 and NRMT2 yielded no
significant alterations in activity when compared to the
wild-type protein.

In contrast, some cancer mutations of

both NRMT1 (N209I and P211S) and NRMT2 (V224L)
significantly altered the catalytic specificity.
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Specifically, the N209I and P211S mutants were found
to require increased time and substrate concentration to
match the activity of wild type NRMT1.

This lead me to

propose that they are slower, catalytically inefficient
enzymes.

Finally, the NRMT2 V224L breast cancer mutant had

little detectable activity.
In Chapter III, I sought to characterize the
significance of the N209I and P211S mutants in a cellular
context.

My approach was to express these mutants and WT

NRMT1 in a knockout line that had been generated by CRISPR
in HCT116 cells (“KO” cells).

As a control, I utilized

HCT116 cells that went through the same process as the KO
cells, except no guide RNAs were used – empty vector (cont.
cells).
Although the results in Chapter II demonstrate that
the cancer mutants are inefficient in vitro, they seem to
lack notable trimethylase activity in cells.

I further

discovered that N209I had increased cytoplasmic
localization compared to the predominantly nuclear
localization of wild type NRMT1 (46,47) and P211S proteins.
Whether this contributes to an oncogenic phenotype is
uncertain at this point.
Having established my rescue cell lines, I then
attempted to assess the importance of the NRMT1 cancer
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mutants in a cellular context.

Based on my data, I

concluded that the expression of the cancer mutants or WT
NRMT1 protein had no effect on KO cells with respect to
proliferation.

Thus, part of my data is in contrast to

what we previously published (109).
Concurrently, I explored the potential effects of the
NRMT1 mutants in the context of DNA damage, given that it
was previously shown that shRNA knockdown of NRMT1 in
breast cancer cells caused an increased sensitivity to DNA
damage (50).

Using the cont., KO, and rescue cell lines, I

induced DNA damage with the chemotherapeutic drug
doxorubicin.

My initial observations indicated that KO

cells may be more sensitive to doxorubicin (either by cell
viability assay or p53/p21 induction). However, the data
was not consistently repeatable.

In conclusion, neither

the KO nor rescue cell lines showed a significant
difference in doxorubicin sensitivity compared to cont.
cells.

Future Biochemical Studies for NRMT1

In Chapter II, I demonstrated that N209I (endometrial
cancer) and P211S (lung cancer) NRMT1 mutants have
decreased trimethylation and increased mono-/dimethylation
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activity toward substrates.

This suggests that the mutants

could have impaired kinetic parameters, and assays should
be performed to determine any alterations to Km and Vmax
values.

Given the increased need of the mutants for time

and substrate levels, alterations to Km, or perhaps Vmax,
seem plausible.

An increase in Km would demonstrate that

the mutants require a higher substrate concentration to
reach half maximal velocity, compared to WT NRMT1.
Furthermore, a decrease in Vmax would demonstrate that the
mutants catalyze methylation reactions at a lower rate
compared to WT NRMT1.
I investigated these questions using several different
methyltransferase assay kits, which measure levels of SAH
(a by-product of methylation reactions).

However, using

full-length recombinant protein, I was unable to detect
much signal over background.

Since I can detect

methylation of substrate by western blot, it is possible
that these assay kits are not sensitive enough to detect
the levels of SAH normally generated by reaction with
NRMT1.

Given this difficulty I encountered using full-

length recombinant protein with multiple assay kits, this
would need to be conducted using peptide substrate.
However, as this would utilize only a small portion of the
N-terminus of the substrate protein, this would be less
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biologically relevant.

An alternative would be to use

full-length protein substrate and measure the kinetics by
radioactive means or metabolite labeling.
In addition to discovering the kinetics of N209I and
P211S, the binding affinity or folding of the mutant
proteins could also be investigated.

Besides the

possibility of N209I and P211S possessing altered kinetic
parameters, contributing to the observed shift in catalytic
specificity, the mutants could also exhibit a decreased
binding affinity for their substrates.

In order to

determine differences in binding affinity between WT NRMT1
and the mutants, isothermal titration calorimetry could be
employed.

It is plausible that the mutants have decreased

substrate binding affinity, which could additionally
contribute to the observed change in catalytic specificity.
Lastly, the folding of the mutants could be studied.
It is possible that the location of the mutants in the
peptide-binding channel of NRMT1, and their hypothesized
effects on the global structure (based on molecular
modeling), could impact the folding of the proteins.

In

order to determine if folding of the proteins are affected
by the mutations, circular dichroism could be utilized.
defect in protein folding could impact the overall
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activity, giving the altered catalytic specificity seen
with the mutants.
Studying the kinetics, binding affinity, and folding
of N209I and P211S may contribute to general biochemical
knowledge of the mutations.

This may be informative for

the cancers that harbor these mutations (N209I, endometrial
cancer; P211S, lung cancer).

Future Studies for NRMT1 and the DNA Damage Response

While my studies suggest that NRTM1 did not play a
role in the DNA damage response in HCT116 cells, it was
shown to do so in breast cancer cell lines (50).

Thus, the

study of DNA damage in breast cancer seems to be a more
appropriate avenue to explore with respect to the NRMT1
cancer mutants that I characterized in Chapter II.
Within the list of potential NRMT1 substrates, only a
handful are involved in the DNA damage response, including
Rb, DDB2, PARP3, and BAP1 (50).

At present, it is unknown

whether or how methylation by NRMT1 facilitates the
function of these targets.

Methylation could affect the

localization of these targets to sites of DNA damage
through direct DNA binding; or, it could regulate proteinprotein interactions crucial for downstream functions.
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For

example, while methylation of DDB2 is necessary for its
recruitment to sites of DNA damage (52), the methylation of
PARP3 is not (118).
Thus, a preliminary working model for how NRMT1 might
function during DNA damage in breast cancer cells is
depicted in Figure 22.

DNA damaging agents, such as

etoposide, cause DSBs, resulting in p53 activation and
transcriptional upregulation of DNA repair proteins, which
can lead to cell survival (178).

One potential role for

NRMT1 could involve the maintenance of p53 expression.
Additionally, NRMT1 may be exerting influence over the DNA
damage response through trimethylation of an unknown
protein.

This methylation could facilitate either the

localization of DNA repair proteins to sites of DNA damage,
or regulate protein-protein interactions, which would
result in downstream localization to the DSBs.

Since the

N209I and P211S mutants do not result in rescue of Nterminal trimethylation in cells, I hypothesize that these
mutants will be incapable of rescuing the sensitivity
towards DNA damage in breast cancer cells deficient in
NRMT1.
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Figure 22. Model of NRMT1 in the DNA damage response.
The role of NRMT1 in the DNA damage response remains
unclear, with the following model proposed.

Upon

doxorubicin treatment, p53 becomes activated and
upregulates the expression of DNA repair proteins, leading
to cell survival.

In response to doxorubicin, NRMT1 is

proposed to influence the expression of p53, which would
further increase DNA repair protein (some of which are
verified NRMT1 substrates) expression and cell survival.
NRMT1 may be exerting additional clout over this response
through trimethylation of an unknown protein, which could
be one of its repair protein substrates, leading to further
cell survival.

As the NRMT1 mutants N209I and P211S do not

rescue N-terminal trimethylation in cells, they are
hypothesized to be incapable of rescuing the effects of the
DNA damage and are therefore proposed to be nonfunctional
in this context.
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Developing More Tools to Study NRMT1 Substrates

There are many putative targets of NRMT1, and one
challenge is to identify specific targets in different
pathways.

One area that needs attention is the lack of

antibodies against other NRMT1 substrate consensus
sequences, besides the existing SPK antibodies.

An example

would include antibodies that recognize the trimethylated
PPK consensus (for targets such as Rb).

A more tedious,

but unbiased, approach would be to employ mass spectrometry
to determine the substrate(s) differentially methylated by
NRMT1 during various cellular processes, such as the DNA
damage response.
Once these differentially methylated substrates are
identified, they can then be tested for their importance in
the pathway.

As an example, suppose there was a substrate

of NRMT1 named “SubX,” for simplicity.

CRISPR/Cas9

methodology could then be utilized to create a knockout
cell line lacking SubX.

Preliminary studies could then

quickly assess the importance of SubX in a pathway.
Subsequently, the knockout cell line would then be
rescued with either wild type SubX or a non-methylatable
mutant.

This would further allow me to determine the

importance of methylation of the protein in the pathway.
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Finally, generation of knockin mice for this mutant will
allow the determination of its physiological importance.

Future Studies for NRMT1 and Oxidative Stress

One important observation gained from the studies of
NRMT1 KO mice and MEFs is their increased sensitivity
towards oxidative stress (51).

Thus, NRMT1 could also act

through this pathway to influence cell survival in response
to certain chemotherapeutic drugs which cause oxidative
stress (179,180).
As an initial study, I would use the H2DCF-DA reagent
(Invitrogen) to detect total cellular ROS levels in NRMT1deficient cells in response to drugs, or other insults
(181).

Using the MitoSOX™ Red reagent (Thermo Fisher

Scientific), which is oxidized by superoxide, would further
allow me to examine mitochondrial ROS generation (182).

If

these preliminary experiments proved fruitful, one could
then utilize state-of-the-art techniques, such as electron
spin resonance (183,184).
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Figure 23. Mutant NRMT1 SPK methylation pattern.
Whole cell lysates from the five featured cell lines were
probed with the tri-SPK (me3RCC1) antibody.
by asterisk is RCC1.

Band indicated

NRMT1 recognizes many substrates with

a variety of consensus sequences; only a handful of those
have the SPK consensus sequence.
loading control.

a-tubulin included as a

Blots are representative images of three

independent experiments.
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Figure 24. Viability studies of HCT116 cells.
Four sets of triplicates were made for each of the five
HCT116 cell lines.

Cells were seeded at a density of 1000

cells per well in 96-well plates.

On the day of plating

(day 0), 20 µl of Aqueous One Solution (Promega, Madison,
WI) was added to the first set of triplicates for each cell
line, and the absorbance at 490 nm was read after two
hours.

Readings were also taken on days 1, 3, and 5.

I) Raw absorbance values are shown on the Y-axis.
panel represents triplicate data.
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Figure 25. Viability assay of doxorubicin-treated cont. and
NRMT1 KO cells.
2.4 X 104 cells per well were seeded into 24-well plates.
Three sets of triplicates were made for cont. and NRMT1 KO
cells.

CellTiter was performed on cells that were treated

with 0.1 or 1 µM doxorubicin (or the untreated controls) for
24 hours.

Following treatment, 80 µl of Aqueous One

Solution was added to each well, and the absorbance at 490
nm was read after two hours.

Y-axis units are arbitrary

units of absorbance at 490 nm.
triplicate data.
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Data points represent
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Figure 26. Viability assay of doxorubicin-treated cells.
2.4 X 104 cells per well were seeded into 24-well plates.
Two sets of triplicates were made for each cell line.
CellTiter was performed on cells that were treated with 1 µM
doxorubicin (or the untreated controls) for 24 hours.
Following treatment, 80 µl of Aqueous One Solution was added
to each well, and the absorbance at 490 nm was read after
two hours.

Y-axis units are arbitrary units of absorbance

at 490 nm.

Data points represent triplicate data.
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Figure 27. siRNA Studies in HCT116 cells.
2.4 X 104 cells per well were seeded into 24-well plates.
Cells were grown until they reached 70% confluency (two
days after seeding).
siRNA.

Cells were transfected with 10 pM

Media was changed 21 hours after transfections.

Two days later, cells were treated with either 1 µM
doxorubicin or 250 µM etoposide (untreated controls were
included, as indicated in the figure) for six hours.

Cell

lysates were collected immediately following treatment.
Lysates were subjected to western blot analysis, probing
with the indicated antibodies.
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Experiment was done once.

APPENDICES: WORK DISCLAIMER

The data appearing in this dissertation are my own and
were performed by me.
and 8-10.

Exceptions to this are Figures 4-6

Figures 4, 9, and 10 were performed by John

Tooley, State University of New York at Buffalo.

The

molecular modeling exhibited in Figure 8 was performed by
Janusz Petkowski, Massachusetts Institute of Technology.
The graph in Figure 5 was created by me but is based upon
the raw mass spectrometry data produced by the University
of Louisville Mass Spectrometry Core Laboratory, which is
displayed in Figure 6.
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catalytic specificity and the DNA damage response.” (2018)
University of Louisville, Department of Biochemistry and
Molecular Genetics Dissertation Defense.

“Investigating the impact of NRMT1 cancer mutants on
catalytic specificity and the DNA damage response.” (2017)
University of Louisville, Department of Biochemistry and
Molecular Genetics Research Conference.

“The role of altered N-terminal methylation in the DNA
damage response.” (2016) University of Louisville,
Department of Biochemistry and Molecular Genetics Research
Conference.
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“Characterizing N-terminal methyltransferase mutations
found in human cancers.” (2015) University of Louisville,
Department of Biochemistry and Molecular Genetics Seminar
Series.

“Histone methylation: what is it good for?” (2015)
University of Louisville, Department of Biochemistry and
Molecular Genetics Seminar Series.

“ADAM10 α-secretase mutations: roles in the progression of
Alzheimer’s Disease.” (2014) University of Louisville,
Department of Biochemistry and Molecular Genetics Seminar
Series.

POSTERS
Shields, K.M., Tooley, J.G., Petkowski, J.J., Wilkey,
D.W., Garbett, N.C., Merchant, M.L., Cheng, A., and
Schaner Tooley, C.E. (2017) Investigating the impact
of NRMT1 cancer mutants on catalytic specificity and
the DNA damage response. 7th Biennial Biochemistry
and Molecular Genetics Colloquium. Louisville,
Kentucky.
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Shields, K.M., Wilkey, D.W., Merchant, M.L., and Schaner
Tooley, C.E. (2015) Characterizing N-terminal
methyltransferase mutations found in human cancers.
Research!Louisville. Louisville, Kentucky.

Shields, K.M., Wilkey, D.W., Merchant, M.L., and Schaner
Tooley, C.E. (2015) Characterizing N-terminal
methyltransferase mutations found in human cancers.
6th Biennial Biochemistry and Molecular Genetics
Colloquium. Louisville, Kentucky.

Shields, K.M. and Schaner Tooley, C.E. (2014)
Characterizing N-terminal methyltransferase mutants
found in human cancers. Research!Louisville.
Louisville, Kentucky.

CONFERENCES
2nd Annual Adjunct Faculty Scholars Conference. (2017)
Indiana University Southeast. New Albany, Indiana.

PROFESSIONAL ASSOCIATIONS
American Chemical Society
American Society for Biochemistry and Molecular Biology
Kentucky Academy of Science
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National Science Teachers Association
Society for College Science Teachers

SERVICE AND EXTRACURRICULAR ACTIVIES
2016-present:

Science fair judge for the Louisville
Regional Science & Engineering Fair

2015-present:

Science fair judge for the DuPont
Manual Regional Science Fair

2015-16:

Graduate Student Council departmental
representative

2012-13:

Science community outreach with MSSU
Chemistry Club

2011-13:

Vice President of MSSU Biology Club

2011-13:

Science fair judge for the Missouri Southern
Regional Science Fair

2011:

Volunteer for Joplin tornado disaster relief
efforts

2010-12:

Deer aging for the Missouri Department of
Conservation
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